AU2001278143B2 - Cyclic polyamine compounds for cancer therapy - Google Patents
Cyclic polyamine compounds for cancer therapy Download PDFInfo
- Publication number
- AU2001278143B2 AU2001278143B2 AU2001278143A AU2001278143A AU2001278143B2 AU 2001278143 B2 AU2001278143 B2 AU 2001278143B2 AU 2001278143 A AU2001278143 A AU 2001278143A AU 2001278143 A AU2001278143 A AU 2001278143A AU 2001278143 B2 AU2001278143 B2 AU 2001278143B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- alkyl
- alkylene
- group
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title claims description 132
- 229920000768 polyamine Polymers 0.000 title description 99
- 125000004122 cyclic group Chemical group 0.000 title description 69
- 238000011275 oncology therapy Methods 0.000 title description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 89
- 206010028980 Neoplasm Diseases 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 57
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 51
- -1 aliphatic aldehyde Chemical class 0.000 claims description 50
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 44
- 201000011510 cancer Diseases 0.000 claims description 41
- 230000000694 effects Effects 0.000 claims description 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 125000002947 alkylene group Chemical group 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- 229940063675 spermine Drugs 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 21
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 125000003277 amino group Chemical group 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 125000006239 protecting group Chemical group 0.000 claims description 15
- DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical group C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 230000002194 synthesizing effect Effects 0.000 claims description 13
- 150000001299 aldehydes Chemical class 0.000 claims description 11
- 125000003368 amide group Chemical group 0.000 claims description 9
- 229940063673 spermidine Drugs 0.000 claims description 9
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 9
- 125000001475 halogen functional group Chemical group 0.000 claims description 8
- 150000002576 ketones Chemical class 0.000 claims description 8
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- 239000002262 Schiff base Substances 0.000 claims description 6
- 150000004753 Schiff bases Chemical class 0.000 claims description 6
- 150000001336 alkenes Chemical class 0.000 claims description 6
- PNTAWGJKWLLAAW-UHFFFAOYSA-N bicyclo[4.1.0]heptane-7-carboxylic acid Chemical compound C1CCCC2C(C(=O)O)C21 PNTAWGJKWLLAAW-UHFFFAOYSA-N 0.000 claims description 6
- 230000002152 alkylating effect Effects 0.000 claims description 5
- 125000004185 ester group Chemical group 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000005700 Putrescine Substances 0.000 claims description 4
- 230000000779 depleting effect Effects 0.000 claims description 4
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical group CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 claims description 4
- 230000029936 alkylation Effects 0.000 claims description 3
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000002560 nitrile group Chemical group 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 claims 4
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 90
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 230000007062 hydrolysis Effects 0.000 description 31
- 238000006460 hydrolysis reaction Methods 0.000 description 31
- 239000000203 mixture Substances 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 26
- 238000000338 in vitro Methods 0.000 description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 16
- 239000012230 colorless oil Substances 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 206010060862 Prostate cancer Diseases 0.000 description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 11
- 230000034659 glycolysis Effects 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 229930186215 budmunchiamine Natural products 0.000 description 9
- 125000004093 cyano group Chemical group *C#N 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 238000010647 peptide synthesis reaction Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000010626 work up procedure Methods 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 150000003335 secondary amines Chemical class 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- HQMOQVLQJSZUTH-UHFFFAOYSA-N 1,9,13-trimethyl-8-undecyl-1,5,9,13-tetrazacycloheptadecan-6-one Chemical compound CCCCCCCCCCCC1CC(=O)NCCCN(C)CCCCN(C)CCCN1C HQMOQVLQJSZUTH-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 6
- 229910004298 SiO 2 Inorganic materials 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229930013930 alkaloid Natural products 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- 231100000582 ATP assay Toxicity 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 5
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 5
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 125000004404 heteroalkyl group Chemical group 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 208000023958 prostate neoplasm Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- BQJBXNLTMGZMKS-UHFFFAOYSA-N 1,9,13-trimethyl-8-tridecyl-1,5,9,13-tetrazacycloheptadecan-6-one Chemical compound CCCCCCCCCCCCCC1CC(=O)NCCCN(C)CCCCN(C)CCCN1C BQJBXNLTMGZMKS-UHFFFAOYSA-N 0.000 description 4
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 4
- 241000524150 Albizia amara Species 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 4
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- OAURMGVSLFVKFS-UHFFFAOYSA-N budmunchiamine B Natural products CCCCCCCCCC1CC(=O)NCCCN(C)CCCCN(C)CCCN1C OAURMGVSLFVKFS-UHFFFAOYSA-N 0.000 description 4
- 150000003857 carboxamides Chemical class 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000000451 chemical ionisation Methods 0.000 description 4
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 150000001923 cyclic compounds Chemical class 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 150000002367 halogens Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229940076788 pyruvate Drugs 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000005309 thioalkoxy group Chemical group 0.000 description 4
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 3
- 108091006296 SLC2A1 Proteins 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 229960003646 lysine Drugs 0.000 description 3
- 150000002678 macrocyclic compounds Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- UMJJGDUYVQCBMC-UHFFFAOYSA-N n-ethyl-n'-[3-[3-(ethylamino)propylamino]propyl]propane-1,3-diamine Chemical compound CCNCCCNCCCNCCCNCC UMJJGDUYVQCBMC-UHFFFAOYSA-N 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 210000005267 prostate cell Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000002407 ATP formation Effects 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- ASCIWXOCZAWSON-UHFFFAOYSA-N Aphelandrine Natural products C1=CC(O)=CC=C1C1C(C(=O)N2CCCNC(=O)CC3NCCCNCCCC2)C2=CC3=CC=C2O1 ASCIWXOCZAWSON-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 102000004225 Cathepsin B Human genes 0.000 description 2
- 108090000712 Cathepsin B Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 102000020897 Formins Human genes 0.000 description 2
- 108091022623 Formins Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000006682 Warburg effect Effects 0.000 description 2
- 238000007239 Wittig reaction Methods 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- HFJRKMMYBMWEAD-UHFFFAOYSA-N dodecanal Chemical compound CCCCCCCCCCCC=O HFJRKMMYBMWEAD-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- WKKVQOAYYIWUKZ-UHFFFAOYSA-N hexadec-2t-enoic acid ethyl ester Natural products CCCCCCCCCCCCCC=CC(=O)OCC WKKVQOAYYIWUKZ-UHFFFAOYSA-N 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 235000014705 isoleucine Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 235000008729 phenylalanine Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000004714 phosphonium salts Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000013930 proline Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 235000014393 valine Nutrition 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ASCIWXOCZAWSON-MSLLRLGPSA-N (11S,17S,18S)-17-(4-hydroxyphenyl)-16-oxa-1,6,10,23-tetrazatetracyclo[9.8.6.212,15.014,18]heptacosa-12,14,26-triene-19,24-dione Chemical compound C1=CC(O)=CC=C1[C@@H]1[C@@H](C(=O)N2CCCNC(=O)C[C@@H]3NCCCNCCCC2)C2=CC3=CC=C2O1 ASCIWXOCZAWSON-MSLLRLGPSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FHYQPVNQLMTVLK-JAVCKPHESA-N (2s)-2-amino-3-(4-hydroxy-4-iodocyclohexa-1,5-dien-1-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CCC(O)(I)C=C1 FHYQPVNQLMTVLK-JAVCKPHESA-N 0.000 description 1
- HCKNRHBSGZMOOF-UHFFFAOYSA-N 1-methoxy-2-methylperoxyethane Chemical compound COCCOOC HCKNRHBSGZMOOF-UHFFFAOYSA-N 0.000 description 1
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
- AOYNUTHNTBLRMT-MXWOLSILSA-N 2-Deoxy-2(F-18)fluoro-2-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H]([18F])C=O AOYNUTHNTBLRMT-MXWOLSILSA-N 0.000 description 1
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 1
- RWSGWOMLOLSMDO-UHFFFAOYSA-N 2-tridecyl-1,5,9-triazacyclotridecan-4-one Chemical compound CCCCCCCCCCCCCC1CC(=O)NCCCNCCCCN1 RWSGWOMLOLSMDO-UHFFFAOYSA-N 0.000 description 1
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 238000004679 31P NMR spectroscopy Methods 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- AJCCLPHPRVPMMX-UHFFFAOYSA-N 8-undecyl-1,5,9,13-tetrazacycloheptadecan-6-one Chemical compound CCCCCCCCCCCC1CC(=O)NCCCNCCCCNCCCN1 AJCCLPHPRVPMMX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 241000722948 Apocynum cannabinum Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- ACPQBYSKUWZMQZ-UHFFFAOYSA-N CC=1C(=C(C=CC1OC)C(=O)C(=O)C1=CC=C(C=C1)OC)C Chemical compound CC=1C(=C(C=CC1OC)C(=O)C(=O)C1=CC=C(C=C1)OC)C ACPQBYSKUWZMQZ-UHFFFAOYSA-N 0.000 description 1
- KSSJBGNOJJETTC-UHFFFAOYSA-N COC1=C(C=CC=C1)N(C1=CC=2C3(C4=CC(=CC=C4C=2C=C1)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC(=CC=C1C=1C=CC(=CC=13)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)OC Chemical compound COC1=C(C=CC=C1)N(C1=CC=2C3(C4=CC(=CC=C4C=2C=C1)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC(=CC=C1C=1C=CC(=CC=13)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)OC KSSJBGNOJJETTC-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 241001015213 Codonocarpus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100034274 Diamine acetyltransferase 1 Human genes 0.000 description 1
- 101710086762 Diamine acetyltransferase 1 Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010063045 Effusion Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930194557 Ephedradine Natural products 0.000 description 1
- 244000085625 Equisetum Species 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102000002686 Formate-Tetrahydrofolate Ligase Human genes 0.000 description 1
- 108010080982 Formate-tetrahydrofolate ligase Proteins 0.000 description 1
- 102100022627 Fructose-2,6-bisphosphatase Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 235000015928 Hibiscus cannabinus Nutrition 0.000 description 1
- IYQSDWNYZAHFOV-UHFFFAOYSA-N Homalin Natural products CN1CCCN2CCCCN(CCCN(C)C(Cc3ccccc3)C2=O)C(=O)C1Cc4ccccc4 IYQSDWNYZAHFOV-UHFFFAOYSA-N 0.000 description 1
- LNCIXDIFZNXBDP-NSOVKSMOSA-N Homaline Chemical compound C1([C@H]2N(C)CCCN(C(C2)=O)CCCCN2CCCN([C@@H](CC2=O)C=2C=CC=CC=2)C)=CC=CC=C1 LNCIXDIFZNXBDP-NSOVKSMOSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001656403 Lunaria Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000549168 Maytenus Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 229910017974 NH40H Inorganic materials 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241001043329 Oncinotis Species 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102100021079 Ornithine decarboxylase Human genes 0.000 description 1
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 1
- 101000840556 Oryza sativa subsp. japonica Hexokinase-4, chloroplastic Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000549085 Peripterygia Species 0.000 description 1
- 108010022678 Phosphofructokinase-2 Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- QEGMJRQKNQFEEZ-UHFFFAOYSA-N Pithecolobine Chemical compound CCCCCCCCCC1CC(=O)NCCCNCCCCNCCCN1 QEGMJRQKNQFEEZ-UHFFFAOYSA-N 0.000 description 1
- QEGMJRQKNQFEEZ-NRFANRHFSA-N Pithecolobine Natural products O=C1NCCCNCCCCNCCCN[C@@H](CCCCCCCCC)C1 QEGMJRQKNQFEEZ-NRFANRHFSA-N 0.000 description 1
- 241000549077 Pleurostylia Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102100035914 S-adenosylmethionine decarboxylase proenzyme Human genes 0.000 description 1
- 108050004491 S-adenosylmethionine decarboxylase proenzyme Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 101710181456 Spermidine N(1)-acetyltransferase Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- HRWHHNKXUUTKNC-UHFFFAOYSA-N [N].C1CNCNC1 Chemical compound [N].C1CNCNC1 HRWHHNKXUUTKNC-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- LIPOUNRJVLNBCD-UHFFFAOYSA-N acetyl dihydrogen phosphate Chemical compound CC(=O)OP(O)(O)=O LIPOUNRJVLNBCD-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 239000002199 base oil Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007726 cellular glucose metabolism Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- OYYHWFZZGWEJQX-UHFFFAOYSA-N chaenorrhine Natural products C1CCNC(=O)CC(C2=CC=C(C(=C2)O2)OC)NCCCN(C(C)=O)CCCCN1C(=O)C=CC1=CC=C2C=C1 OYYHWFZZGWEJQX-UHFFFAOYSA-N 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- FQTIYMRSUOADDK-UHFFFAOYSA-N ethyl 3-bromopropanoate Chemical compound CCOC(=O)CCBr FQTIYMRSUOADDK-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- GZXNVYMVJSTRNI-UHFFFAOYSA-N ethyl dodec-2-enoate Chemical compound CCCCCCCCCC=CC(=O)OCC GZXNVYMVJSTRNI-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- JXDGEQAWGZXILF-UHFFFAOYSA-N ethyl tetradec-2-enoate Chemical compound CCCCCCCCCCCC=CC(=O)OCC JXDGEQAWGZXILF-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- TVISEJUYYBUVNV-UHFFFAOYSA-N formyl dihydrogen phosphate Chemical compound OP(O)(=O)OC=O TVISEJUYYBUVNV-UHFFFAOYSA-N 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000007946 glucose deprivation Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000010930 lactamization Methods 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000006502 nitrobenzyl group Chemical group 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 101150061302 och1 gene Proteins 0.000 description 1
- 108091008820 oncogenic transcription factors Proteins 0.000 description 1
- ASCIWXOCZAWSON-RNJDCESWSA-N orantine Chemical compound C1=CC(O)=CC=C1[C@H]1[C@H](C(=O)N2CCCNC(=O)C[C@@H]3NCCCNCCCC2)C2=CC3=CC=C2O1 ASCIWXOCZAWSON-RNJDCESWSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229930001122 polyamine alkaloid Natural products 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 231100000916 relative toxicity Toxicity 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- DODDBCGMRAFLEB-UHFFFAOYSA-N thermospermine Chemical compound NCCCCNCCCNCCCN DODDBCGMRAFLEB-UHFFFAOYSA-N 0.000 description 1
- ZAXCZCOUDLENMH-UHFFFAOYSA-N thermospermine Natural products NCCCNCCCNCCCN ZAXCZCOUDLENMH-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
WO 02/10142 PCT/US01/24282 CYCLIC POLYAMINE COMPOUNDS FOR CANCER THERAPY CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to Provisional Patent Application Number 60/222,522 filed August 2, 2000, the content of which is incorporated herein by reference in its entirety.
TECHNICAL FIELD [0002] This invention is directed to compounds and methods useful for treating cancer and other diseases caused by uncontrolled cell proliferation. More specifically, this invention is directed to cyclic polyamine compounds which display anti-tumor activity in vitro, as well as methods of making and using those compounds.
BACKGROUND OF THE INVENTION [0003] Cancer is one of the leading causes of death in the developed world. Approximately one-quarter of the deaths in the United States in 1997 were due to cancer, making it the second most common cause of death after heart disease. Accordingly, development of new and effective treatments for cancer is a high priority for health care researchers.
[0004] Cancer is often treated by using chemotherapy to selectively kill or hinder the growth of cancer cells, while having a less deleterious effect on normal cells. Chemotherapeutic agents often kill rapidly dividing cells, such as cancer cells; cells which are dividing less rapidly are affected to a lesser degree. Other agents, such as antibodies attached to toxic agents, have been evaluated for use against cancers. These agents target the cancer cells by making use of a characteristic specific to the cancer, for example, higher-than-normal rates of cell division, or unique antigens expressed on the cancer cell surface.
WO 02/10142 PCT/US01/24282 [0005] One peculiar distinguishing characteristic of malignant cells is their high rate of glycolysis, even in the presence of oxygen (so-called aerobic glycolysis, or the Warburg effect). Studies by Otto Warburg over seven decades ago demonstrated that the vast majority of human and animal tumors display a high rate of glycolysis. Although Warburg's hypothesis that defective oxidative metabolism underlies this high rate of glycolysis is not supported by recent studies, the original observation has been fully confirmed. See Chesney, J. et al., "An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect," Proc.
Natl. Acad. Sci. USA (1999) 96(6):3047-52. Human tumors endure profound hypoxia, and hence adaptation to hypoxic conditions is a crucial step in tumor progression. The anaerobic use of glucose as an energy source through glycolysis is therefore a feature common to most solid tumors. See Dang, C.V. and Semenza, "Oncogenic alterations of metabolism," Trends Biochem. Sci.
(1999) 24(2):68-72 and Boros, L.G. et al., "Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: is cancer a disease of cellular glucose metabolism?" Med. Hypotheses (1998) 50(1):55-9 [0006] Magnetic resonance spectroscopy and positron-emission tomography have demonstrated that tumors have an increased uptake of glucose as compared with normal tissues, and that tumor aggressiveness and prognosis correlates with glucose uptake. See Imdahl, A. et al., "Evaluation of positron emission tomography with 2-[ 1 8 F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer," Br. J. Surg. (1999) 86(2):194-9 and Maublant, J. et al., "Positron emission tomography (PET) and (F-18)fluorodeoxyglucose in (FDG) in cancerology," Bull. Cancer (Paris) (1998) 85(11):935-50. The expression of the glucose transporter GLUT1 is also increased in cancer cells. See Grover-McKay, M. et al., "Role for glucose transporter 1 protein in human breast cancer," Pathol. Oncol. Res. (1998) 4(2):115-20 and Burstein D.E. et al., "GLUT1 glucose transporter: a highly sensitive marker of malignancy in body cavity effusions," Mod. Pathol. (1998) 11(4):392-6. Glucose utilization through the glycolytic pathway in cancer cells 2 WO 02/10142 PCT/US01/24282 leads to pyruvate formation as is the case in normal cells, but in the absence of oxygen, pyruvate is not metabolized through the tricarboxylic cycle. This deprives the cancer cells of the efficient production of ATP by oxidative phosphorylation. In cancer cells pyruvate is reduced (by NADPH) to lactate, leading to the acidic environment of tumors. The cytosolic pH of tumor cells, however, is maintained as it is in normal cells. See Dang, C.V. and Semenza, "Oncogenic alterations of metabolism," Trends Biochem. Sci. (1999) 24(2):68-72.
[0007 Hypoxia is a strong selective force, and it regulates glycolysis by modulating oncogenes and tumor suppressing genes. Tumor angiogenesis is stimulated by hypoxia and hypoglycemia, which induce expression of angiogenic factors that recruit microvessels to allow delivery of nutrients and oxygen, to support expansion of the tumor mass. See Moser, T.L. et al., "Angiostatin binds ATP synthase on the surface of human endothelial cells," Proc. Natl. Acad. Sci.
USA (1999) 96(6):2811-6. However, the new microvessels are limited and disorganized, and the oxygen consumption rate exceeds the supply rate. Glucose deprivation is a potent inducer of necrosis in transformed cells, and physiological and oncogenic transcription factors that stimulate glycolysis by increasing glucose transport as well as the activity of key glycolytic enzymes hexokinase II, lactate dehydrogenase A) play a crucial role in promoting the survival of cancer cells in adverse tumor microenvironments. See Blancher C. et al., "The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target," Cancer Metastasis Rev. (1998) 17(2):187-94.
[0008] Cancer cells thus depend mainly on the glycolytic pathway to generate the necessary ATP to grow, even in the presence of oxygen. It is known that the energy provided by one mole of ATP is needed to produce 10 g of cells.
While the aerobic oxidation of one mole of glucose to carbon dioxide results in a net gain of ca. 38 moles of ATP, the anaerobic (glycolytic) transformation of 1 mole of glucose into pyruvate and lactate only results in the gain of 2 moles of ATP, 19 times less than in aerobic oxidation. It is clear that ATP is very much at WO 02/10142 PCT/US01/24282 a premium in cancer cells due to the incomplete oxidation of glucose in the cells, which in turn requires an elevated rate of glycolysis in tumor cells.
[0009] Because of the limited supply and high demand for ATP in malignant cells, drugs which can hydrolyze ATP can provide a means to control cancer growth. Such a drug will disproportionately impact a cancer cell, while being less deleterious to normal tissue where ATP synthesis is constantly replenished by oxidative phosphorylation in the mitochondria.
[0010] Early note was taken of the various functions that cyclic polyamines can perform. These functions include facilitating selective uptake and transport of metal ions, metal chelation, and serving as models of catalyst and enzyme function. See Kimura, "Macrocyclic polyamines with intelligent functions," Tetrahedron (1992) 48(30):6175.
[0011] Cyclic polyamines have been observed to have surprising effects on ATP hydrolysis. Cyclic polyamines, when protonated, bind ATP, ADP, and AMP stably and enhance the rate of hydrolysis of ATP by several orders of magnitude over a wide pH range. Linear polyamines, which do not bind ATP, do not increase the rate of hydrolysis. Hydrolysis catalyzed by a cyclic compound yields orthophosphate and ADP as products; the ADP is then hydrolyzed slowly to AMP. In the cleavage of ATP, the formation of an intermediate phosphoramidate was detected and the possible form of an initial "perched" complex and a mechanism of hydrolysis were postulated. See Merthes, M.P. et al., "Polyammonium macrocycles as catalysts for phosphoryl transfer: the evolution of an enzyme mimic," Account of Chemical Research (1990) 23:413; Hosseini, M.W. et al, "Efficient molecular catalysis of ATP hydrolysis by protonated macrocyclic polyamines," Helv. Chim. Acta (1983) 66:2454; Prakash, T.P. et al., "Macrocyclic polyamine[16]-N3 and [21]-N4: Synthesis and study of their ATP complexation by 31 P NMR spectroscopy," J. Chem. Soc. Perkin Trans.
(1991) 1:1273; Hosseini, M.W. et al., "Supramolecular catalysis in the hydrolysis of ATP facilitated by macrocyclic polyamines: mechanistic studies," J. Am.
Chem. Soc. (1987) 109:537; and Bencini, A. et al., "Potential ATPase mimics by polyammonium macrocycles: criteria for catalytic activity," Bioorganic Chem.
4 WO 02/10142 PCT/US01/24282 (1992) 20:8. These cyclic catalysts were described as "functional mimics" of ATPases. The hydrolysis of ATP involved an exchange of oxygen at the beta-phosphate of ATP and occurred in the presence of calcium. Under these conditions, subsequent hydrolysis of ADP was decreased and the phosphorylated cyclic compound accumulated. When this reaction mixture was adjusted to pH pyrophosphate was formed. The cyclic phosphoramidate was shown to be capable of phosphorylating ADP to give ATP.
[0012] The phosphatase activity of the cyclic polyamines was also studied using other biological phosphate esters. It was shown that a cyclic polyamine catalyst cleaved acetyl phosphate to orthophosphate; the reaction then proceeded to the synthesis of pyrophosphate. It has been observed that a cyclic polyamine could activate formate in an ATP-dependent reaction in the presence of Ca++ or The activation appeared to proceed via the hydrolysis of ATP to generate the cyclic phosphoramidate, with the latter species forming the proposed intermediate formyl-phosphate that was then cleaved on the cycle to produce a cyclic formamide (N-formylation). It has been suggested that this set of reactions might mimic the ATP-dependent enzymatic synthesis of Nl'-formyl tetrahydrofolate and is relevant to the nature of formyl tetrahydrofolate synthetase. See Jahansouz H. et al., "Formate activation of neutral aqueous solutions mediated by a polyammonium macrocycle," J. Am. Chem. Soc. (1989) 111:1409.
[0013] Independent of the chemical studies described above with cyclic polyamines and with cyclic polyethers (Kimura et al., supra) it was known from the phytochemical literature that cyclic polyamine alkaloids (also called macrocyclic aminolactams) are an important class of natural products. They originate mainly from the crossover of the phenylpropanoid biosynthetic pathway (the shikimate pathway) and the polyamine (spermine and spermidine) pathway.
Thus, from the plant families Cannabis (indian hemp), Codonocarpus, Equisetum (horsetail), Lunaria, Maytenus, Oncinotis, Peripterygia, and Pleurostylia the following cyclic spermidine-derived alkaloids, among others, were isolated: chaenorhine, aphelandrine, orantin, the ephedradines, and the periphyllines. See WO 02/10142 PCT/US01/24282 Gerardy, R. et al., Phytochemistry (1993) 32:79; Zenk, M.H. et al., J. Chem. Soc.
Chem. Commun. (1989) 1725; Husson, et al., Tetrahedron (1973) 29:1405; Sagner, S. et al., Tetrahedron Letters (1997) 38:2443; Stach, H. et al., Tetrahedron (1988) 44:1573; and Kramer, U. et al., Angew. Chem. (1977) 89:899. Among the spermine-derived alkaloids are homaline and the mixture of alkaloids called pithecolobines. The latter were isolated from extracts ofPithecolobium saman (see Wiesner, K. et al., "Structure ofpithecolobine II," Can. J. Chem. (1968) 46:1881 and Wiesner, K. et al., "Structure of pithecolobine III," Can. J. Chem.
(1968) 46:3617) and their biosynthesis likely derives from the crossover of the metabolism of spermine with the metabolic pathways for unsaturated fatty acids.
From the seeds of the Indian plant Albizia amara, a methanol extract was shown to contain a mixture of nine alkaloids that were called budmunchiamines A to I.
See Pezzuto, J.M. et al., "DNA-based isolation and the structure elucidation of the budmunchiamines, novel macrocyclic alkaloids from Albizia amara," Heterocycles (1991) 32:1961-68; Pezzuto, J.M. et al., Phytochemistry (1992) 31:1795-1800. Their structures were established by physical methods and were found to be analogous to the pithecolobines. Isolates from the seeds of Albizia amara were found to have cytotoxic effects in a general screen for possible biological effects. Mar, W. et al., "Biological activity of novel macrocyclic alkaloids (budmunchiamines) from Albizia amara detected on the basis of interaction with DNA," J. Natural Products (1991) 54:1531. Other studies regarding budmunchiamines are described in Rukunga, G.M. et al., J. Nat. Prod.
59(9):850-3 (1996); Rukunga, G.M. et al., Phytochemistry 42(4):1211-15 (1996); Misra, L.N. et al., Phytochemistry 39(1):247-249 (1995); Dixit, A.K. et al., J. Nat.
Prod. 60(10):1036-1037 (1997); Rukunga, G.M. et al., Bull. Chem. Soc. Ethiopia 10(1):47-51 (1996); Cordell, G.A. et al., Pure Appl. Chem. 66(10-1):2283-2286 (1994); and Onuki, H. et al., Tetr. Lett., 34(35):5609-5612 (1993).
[0014] However, the above-referenced art does not suggest use of isolated cyclic polyamines for cancer therapy, nor does it provide guidance to use cyclic polyamines as in vivo catalysts of hydrolysis ofintracellular ATP in cancer cells.
Thus, the cyclic polyamines of the present invention represent a new approach to 6 WO 02/10142 PCT/US01/24282 cancery therapy. Additionally, no syntheses of the budmunchiamine compounds have been reported, and work with budmunchiamines has typically been performed with plant extracts containing a mixture of compounds. The present invention provides methods that allow the synthesis of individual compounds similar to the structures proposed for the pithecolobines and the budmunchiamines, in order to design new compounds with ATP-ase-like activity in vivo and permit study of the isolated compounds. Such new compounds were created with the methods of the present invention for use in treating cancer and other pathological conditions.
DISCLOSURE OF THE INVENTION [0015] The invention provides compounds and compositions for treating diseases caused by uncontrolled proliferation of cells, such as cancer, especially prostate cancer, and for inducing intracellular ATP hydrolysis for treatment of other disorders.
[0016] In one embodiment, the invention provides compounds of the
O
Y N 1A3"N A 2 R N N k Y Y formula: where A 1 each A 2 (if present), and A 3 are independently selected from Ci-
C
8 alkyl; where each Y is independently selected from H or Ci-C 4 alkyl; where M is selected from C 1
-C
4 alkyl; where k is 0, 2, or 3; and where R is selected from
C
1
-C
3 2 alkyl; and all stereoisomers and salts thereof. In additional embodiments, the Y group is -H or -CH 3 In another embodiment, A 1 each A 2 (if present), and A3 are independently selected from C 2
-C
4 alkyl. In yet another embodiment, M is
-CH
2 The invention also includes compositions of one or more of the compounds above in combination with a pharmaceutically-acceptable carrier.
WO 02/10142 PCT/US01/24282 [0017] The invention also provides compounds of the formula:
O
M N. ANY Y I
SA
3
A
2 Y Y where A 1 and A 3 are independently selected from Ci-Cg alkyl; where A 2 is independently selected from C 1
-C
3 alkyl or C 5
-C
8 alkyl; where each Y is independently selected from H or C 1
-C
4 alkyl; where M is selected from CI-C 4 alkyl; and where R is selected from Ci-C 3 2 alkyl; and all stereoisomers and salts thereof. In additional embodiments, the Y group is -H or -CH 3 In another embodiment, A 1 and A 3 are independently selected from C 2
-C
4 alkyl, and A 2 is selected from the group consisting of C 2
-C
3 alkyl and C 5 alkyl. In yet another embodiment, M is -CH 2 The invention also includes compositions of one or more of the compounds above in combination with a pharmaceutically-acceptable carrier.
[0018] The invention also provides compounds of the formula:
O
M N, NANY Y
I
R /A 3 N/ A 2 Y Y where Al and A 3 are independently selected from Ci-C 8 alkyl; where A 2 is independently selected from Ci-C 8 alkyl; where each Y is independently selected from H or C 2
-C
4 alkyl; where M is selected from Ci-C 4 alkyl; and where R is selected from C 1
-C
32 alkyl; and all stereoisomers and salts thereof. In an additional embodiment, each Y group is In another embodiment, A 1 and A 3 WO 02/10142 PCT/US01/24282 are independently selected from C 2
-C
4 alkyl, and A 2 is selected from the group consisting of Cz-C 5 alkyl. In yet another embodiment, M is -CHz-. The invention also includes compositions of one or more of the compounds above in combination with a pharmaceutically-acceptable carrier.
[0019] The invention also provides a method of synthesizing a compound of the formula
O
M N A NY R N N k Y Y where A i each A 2 (if present), and A 3 are independently selected from C 1 Cs alkyl; where each Y is independently selected from H or C 1
-C
4 alkyl; where M is selected from Ci-C 4 alkyl; where k is 0, 1, 2, or 3; and where R is selected from
C
1
-C
32 alkyl; where the method comprises the steps of reacting an (-halo alkyl alkanoate with an aldehyde or ketone-containing compound to give an alkenecontaining alkanoate compound; reacting the alkene-containing alkanoate compound with a compound containing two primary amino groups and optionally containing secondary amino groups to effect addition of one of the amino groups across the double bond; cyclizing the other amino group with the alkanoate group to form an amide bond; and optionally alkylating the secondary amino groups if present. In one embodiment, the c0-halo alkyl alkanoate is ethyl bromoacetate. In another embodiment, the aldehyde or ketone-containing compound is an aldehyde-containing compound. In yet another embodiment, the step of reacting an co-halo alkyl alkanoate with an aldehyde or ketone-containing compound to give an alkene-containing alkanoate compound is performed by reacting the o)halo alkyl alkanoate with triphenylphosphine. In still another embodiment, the compound containing two primary amino groups is selected from the group consisting of H 2
N-AI-(NH-A
2 )k-NH-A 3
-NH
2 where A 1 each A 2 (if present), and WO 02/10142 PCT/US01/24282
A
3 are independently selected from Ci-Cs alkyl and k is 0, 1, 2, or 3. The compound containing two primary amino groups can be selected from the group consisting of spermine, spermidine, and putrescine in still another embodiment.
The step of cyclizing the other amino group with the alkyl alkanoate group to form an amide bond can be performed by reacting the compound with antimony (III) ethoxide in yet another embodiment. In an additional embodiment, the step of optionally alkylating any secondary amino groups, if present, can performed by reacting the compound first with an aliphatic aldehyde to result in a Schiffbase, then reducing the Schiffbase, resulting in alkylation of the secondary amino groups; the step of reducing the Schiff base can be performed by using the reagent NaCNBH 3 [0020] The invention also provides a method of synthesizing a compound of the formula:
O
M N A NY Y I j R A 3
A
2 R N N k WO 02/10142 PCT/US01/24282 where A 1 is C 3 alkyl, and each Az (if present) and A 3 are independently selected from C 1
-C
8 alkyl; where each Y is independently selected from H or Ci-
C
4 alkyl; where M is selected from Ci-C 4 alkyl; where k is 0, 1, 2, or 3; and where R is selected from C 1
-C
3 2 alkyl; where the method comprises the steps of condensing a compound comprising a primary amino group and a hexahydropyrimidine moiety with an a,3-unsaturated ester compound, such that the primary amino group adds at the P-position of the unsaturated ester compound, whereby the primary amino group is converted to a secondary amino group; cleaving the methylene bridge of the hexahydropyrimidine moiety to generate a secondary amino group and a newly-generated primary amino group; and condensing the newly-generated primary amino group with the ester group to form an amide group. The a,P-unsaturated ester can be of the formula (Ci-Cs alkyl)-O-C(=O)-CH=CH-(C 1
-C
32 alkyl). In another embodiment, the compound comprising a primary amino group and a hexahydropyrimidine moiety is of the formula
H
2
N-A
3
-(NY-A
2 )j-N NH where each A 2 (if present) and A 3 are independently selected from Ci-C alkyl; where each Y is independently selected from H or C 1
-C
4 alkyl; and where j is 0, 1, 2, or 3. In a preferred embodiment, j is 0. In another preferred embodiment, A 3 is C 4 alkyl. The step of cleaving the methylene bridge of the hexahydropyrimidine moiety can be performed with anhydrous HCI in an alcoholic solvent. The step of condensing the newly-generated primary amino group with the ester group to form an amide group can be performed with the reagent B(N(CH 3 2 3 [0021] The invention also provides compounds of the formula WO 02/10142 PCT/US01/24282 M N NY R /A3N A 2 Y Y where A 1 each A 2 (if present), and A 3 are independently selected from C 1 Cs alkyl; where A 4 is selected from C 1
-C
8 alkyl or a nonentity; where X is selected from -CN, -NH 2 -C(=O)-Ci-C 8 alkyl, or -NHZ, with the proviso that when A 4 is a nonentity, X is -C(=O)-Ci-C 8 alkyl, or where Z is selected from the group consisting of an amino protecting group, an amino capping group, an amino acid, and a peptide; where each Y is independently selected from H or C 1
-C
4 alkyl; where M is selected from C 1
-C
4 alkyl; where k is 0, 1, 2, or 3; and where R is selected from C 1
-C
32 alkyl; and all stereoisomers and salts thereof. In certain embodiments, A 4 is a nonentity. In other embodiments, X is and -Z is In other embodiments, Y is -CH3. In other embodiments, M is -CH2-. In still further embodiments, k is 1. In further embodiments, A 1 and A 3 are -CH2CH 2
CH
2 In still further embodiments, -CH 2
CH
2
CH
2
CH
2 In still further embodiments, R is -C 13
H
2 7. In yet further embodiments, one or more of the specific limitations on A 4 X, Z, Y, M, k, A 1
A
3 and R are combined.
[0022] In further embodiments of these compounds, A4 is C-C8 alkyl, X is -NHZ, and Z is selected from one of the 20 genetically encoded amino acids (alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, tyrosine), a peptide of the formula acetyl-SKLQL-, a peptide of the formula acetyl-SKLQ--alanine-, or a peptide of the formula acetyl-SKLQ-.
[0023] The invention also provides methods of synthesizing compounds of the formula WO 02/10142 PCT/US01/24282
H
M N NY R N N k Y Y by reducing the carbonyl of the amide group of a compound of the formula 0
H
M N NY R N' Nl k Y Y where A i each A 2 (if present), and A 3 are independently selected from Ci-
C
8 alkyl; where each Y is independently selected from H or Ci-C 4 alkyl; where M is selected from Ci-C 4 alkyl; where k is 0, 1, 2, or 3; and where R is selected from
C
1
-C
32 alkyl; and all stereoisomers and salts thereof. Lithium aluminum hydride may be used as the reducing agent. Diborane may also be used as the reducing agent.
[0024] The invention also provides a method of synthesizing a compound of the formula
CN
M N NY
SA
3 A2 WO 02/10142 PCT/US01/24282 where A 1 each A 2 (if present), and A 3 are independently selected from C 1 Cs alkyl; where each Y is independently selected from C 1
-C
4 alkyl; where M is selected from C 1
-C
4 alkyl; where k is 0, 1, 2, or 3; and where R is selected from
C
1
-C
3 2 alkyl, comprising reacting a compound of the formula
H
M N NY R NI NI A 2 k Y Y where Ai, each A 2 (if present), and A 3 are independently selected from Ci-
C
8 alkyl; where each Y is independently selected from Ci-C 4 alkyl; where M is selected from C 1
-C
4 alkyl; where k is 0, 1, 2, or 3; and where R is selected from
C
1
-C
3 2 alkyl, with a compound of the formula H 2
C=CH-CN.
[0025] The invention also provides a method of synthesizing compounds of the formula
NH
2 M N NY R N NI i k Y Y where A l each A 2 (if present), and A 3 are independently selected from C 1
C
8 alkyl; where each Y is independently selected from C 1
-C
4 alkyl; where M is selected from C 1
-C
4 alkyl; where k is 0, 1, 2, or 3; and where R is selected from
C
1
-C
3 2 alkyl, by reducing the nitrile group of a compound of the formula M N NY A3A A 2 0 0 2 SY
Y
(where A, each A 2 (if present), and A 3 are independently selected from Ci- C 8 alkyl where each Y is independently selected from C|-C 4 alkyl where M is selected from Ci-C 4 alkyl where k is 0,1,2, or 3; and where R is selected from CI-C 32 alkyl) to an amino group. A preferred reducing reagent is gaseous hydrogen (H 2 over Raney nickel.
[0026] The invention also provides methods of treating diseases characterized by uncontrolled cell proliferation, such as cancer, especially prostate cancer, by administration of one or more of the compounds described above. The invention also provides methods of depleting ATP, particularly in a cancerous cell, by administration of one or more of the compounds described above. The invention also includes compositions of one or more of the compounds described above in combination with a pharmaceutically-acceptable carrier, or with another therapeutic agent.
165894_l.doc C The present invention also provides a compound of the formula t0 SN A1 NY-A2k wherein each A 2 (if present), and A 3 are independently selected from Ci-C 8 alkylene; wherein each Y is independently selected from H or CI-C 4 alkyl; wherein M is selected from C 1
-C
4 alkylene; wherein k is 0, 2, or 3; and wherein R is selected from CI-C 32 alkyl; and all stereoisomers and salts thereof.
The present invention also provides a compound of the formula 0 N A1N M N NY Y
I
SA
3 A 2 Y Y wherein A and A 3 are independently selected from Ci-C 8 alkylene; wherein A 2 is independently selected from CI-C 3 alkylene or C 5 -C alkylene; wherein each Y is independently selected from H or Ci-C 4 alkyl; wherein M is selected from CI-C 4 alkylene; and wherein R is selected from CI-C 32 alkyl; and all stereoisomers and salts thereof.
The present invention also provides a compound of the formula 165894 1.doc 0 M N NY
Y
A 3
A
2 R N N C Y Y C1 5 wherein Al and A 3 are independently selected from CI-C 8 alkylene; wherein A 2 is independently selected from Ci-C 8 alkylene; wherein each Y is independently selected from H or C 2
-C
4 alkyl; wherein M is selected from CI-C 4 alkylene; and wherein R is selected from CI-C 32 alkyl; and all stereoisomers and salts thereof.
The present invention also provides a method of synthesizing a compound of the formula 0 M j N AiNY-A2 k
SY
R N A3NY
Y
wherein each A 2 (if present), and A 3 are independently selected from Ci-C 8 alkylene; wherein each Y is independently selected from H or Ci-C 4 alkyl; wherein M is selected from Ci-C 4 alkylene; wherein k is 0, 1, 2, or 3; and wherein R is selected from Ci-C 32 alkyl; comprising the steps of: reacting an o-halo alkyl alkanoate with an aldehyde or ketone-containing compound to give an alkene-containing alkanoate compound; 165894 l.doc reacting the alkene-containing alkanoate compound with a compound containing two primary amino groups and optionally containing secondary amino groups to effect addition of one of the amino groups across the double bond; cyclizing the other amino group with the alkanoate group to form an amide bond; and C optionally alkylating the secondary amino groups if present.
The present invention also provides a method of synthesizing a compound of the 00 Sformula O O
Y
wherein A, is C 3 alkylene, and each A 2 (if present) and A 3 are independently selected from C,-C 8 alkylene; wherein each Y is independently selected from H or Ci-C 4 alkyl; wherein M is selected from CI-C 4 alkylene; wherein k is 0, 1, 2, or 3; and wherein R is selected from C 1
-C
3 2 alkyl; comprising the steps of: condensing a compound comprising a primary amino group and a hexahydropyrimidine moiety with an a,p-unsaturated ester compound such that the primary amino group adds at the P-position of the unsaturated ester compound, whereby the primary amino group is converted to a secondary amino group; cleaving the methylene bridge of the hexahydropyrimidine moiety to generate a secondary amino group and a newly-generated primary amino group; and condensing the newly-generated primary amino group with the ester group to form an amide group.
The present invention also provides a compound of the formula 165894 1.doc S 'N L J k
Y
00 R N NY
Y
wherein Ai, each A 2 (if present), and A 3 are independently selected from Ci-C 8 alkylene; wherein A 4 is selected from CI-C 8 alkylene or a nonentity; X is selected from -CN, -NH 2 -C(=O)-Cl-C 8 alkyl, or -NHZ, with the provisos that when A 4 is a nonentity, X is -C(=O)-Ci-Cs alkyl, or and that when X is -Z,
A
4 is a nonentity; Z is selected from the group consisting of an amino protecting group, an amino capping group, an amino acid, and a peptide; wherein each Y is independently selected from H or CI-C 4 alkyl; wherein M is selected from Ci-C 4 alkylene; wherein k is 0, 1, 2, or 3; and wherein R is selected from CI-C 32 alkyl; and all stereoisomers and salts thereof.
Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
165894 1.doc 0BRIEF DESCRIPTION OF THE DRAWINGS ¢C [0027] Fig. 1 is a graph showing the in vitro effect of increasing concentration of- 11174 on the growth of cultured human prostate cancer cell DuPro.
00 [0028] Fig. 2 is a graph showing the in vitro effect of increasing concentration of SL- 11197 on the growth of cultured human prostate cancer cell DuPro.
165894 l.doc WO 02/10142 PCT/US01/24282 [0029] Fig. 3 is a graph showing the in vitro effect of increasing concentration of SL- 11199 on the growth of cultured human prostrate cancer cell DuPro.
[0030] Fig. 4 is a graph showing the in vitro effect of increasing concentration of SL-11200 on the growth of cultured human prostrate cancer cell DuPro.
[0031] Fig. 5 is a graph showing the in vitro effect of increasing concentration of SL-11208 on the growth of cultured human prostrate cancer cell DuPro.
[0032] Fig. 6 is a graph showing the effect of SL-11174 on the survival of cultured human prostate cancer cell DuPro.
[0033] Fig. 7 is a graph showing the effect of SL-11197 on the survival, of cultured human prostate cancer cell DuPro.
[0034] Fig. 8 is a graph showing the effect of SL-11199 on the survival of cultured human prostate cancer cell DuPro.
[0035] Fig. 9 is a graph showing the effect of SL-11200 on the survival of cultured human prostate cancer cell DuPro.
[0036] Fig. 10 is a graph showing the effect of SL-11208 on the survival of cultured human prostate cancer cell DuPro.
[0037] Fig. 11 depicts the effect of SL-1 1238 on DuPro cell growth.
[0038] Fig. 12 depicts the effect of SL-11239 on DuPro cell growth.
[0039] Fig. 13 depicts the effect of SL-11238 on survival of DuPro cells.
[0040] Fig. 14 depicts the effect of SL-11239 on survival of DuPro cells.
[0041] Fig. 15 depicts the in vitro effect of spermine (control) and SL-11174 on ATP hydrolysis [0042] Fig. 16 depicts the in vitro effect of spermine (control) and SL-11197 on ATP hydrolysis.
[0043] Fig. 17 depicts the in vitro effect of spermine (control) and SL-11199 on ATP hydrolysis.
[0044] Fig. 18 depicts the in vitro effect of spermine (control) and SL-11200 on ATP hydrolysis.
WO 02/10142 PCT/US01/24282 [00451 Fig. 19 depicts the in vitro effect of spermine (control) and SL-11208 on ATP hydrolysis.
[0046] Fig. 20 depicts the in vitro effect of SL-11238 on ATP hydrolysis.
[0047] Fig. 21 depicts the in vitro effect of SL-11239 on ATP hydrolysis.
[0048] Fig. 22 depicts the mean relative changes in luciferin/luciferase activities and standard deviations in the presence of extracts of 50,000 cultured human prostate tumor cells (DuPro) treated with varying concentrations of SL-11174, SL-11197, SL-11199, SL-11200, and SL-11208. Standard deviations, where not seen, are smaller than the symbol size.
[0049] Fig. 23 depicts the effect of SL-11238 on cellular ATP measured by the luciferin/luciferase reaction.
[0050] Fig. 24 depicts the effect of SL-1 1239 on cellular ATP measured by the luciferin/luciferase reaction.
BEST MODE FOR CARRYING OUT THE INVENTION [0051] Reference is made throughout the Detailed Description to the reaction Schedules and Tables included herein. For sake of clarity and brevity, reference numerals have been assigned to each chemical structure described.
These reference numerals are used consistently throughout the disclosure to unambiguously designate the chemical entities discussed.
[0052] The invention includes all salts of the compounds described herein.
Particularly preferred are pharmaceutically acceptable salts. Pharmaceutically acceptable salts are those salts which retain the biological activity of the free bases and which are not biologically or otherwise undesirable. The desired salt may be prepared by methods known to those of skill in the art by treating the polyamine with an acid. Examples of inorganic acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Examples of organic acids include, but are not limited to, formic acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic WO 02/10142 PCT/US01/24282 acid, mandelic acid, sulfonic acids, and salicylic acid. Salts of the polyamines with amino acids, such as aspartate salts and glutamate salts, can also be prepared.
[0053] The invention also includes all stereoisomers of the compounds, including diastereomers and enantiomers, as well as mixtures of stereoisomers, including, but not limited to, racemic mixtures. Unless stereochemistry is explicitly indicated in a structure, the structure is intended to embrace all possible stereoisomers of the compound depicted.
[0054] The term "alkyl" refers to saturated aliphatic groups including straight-chain, branched-chain, cyclic groups, and combinations thereof, having the number of carbon atoms specified, or if no number is specified, having up to 12 carbon atoms. Examples of alkyl groups include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, npentyl, neopentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and adamantyl. Cyclic groups can consist of one ring, including, but not limited to, groups such as cycloheptyl, or multiple fused rings, including, but not limited to, groups such as adamantyl or norbornyl. Alkyl groups may be unsubstituted, or may be substituted with one or more substituents including, but not limited to, groups such as halogen (fluoro, chloro, bromo, and iodo), alkoxy, acyloxy, amino, hydroxyl, mercapto, carboxy, benzyloxy, phenyl, benzyl, cyano, nitro, thioalkoxy, carboxaldehyde, carboalkoxy and carboxamide, or a functionality that can be suitably blocked, if necessary for purposes of the invention, with a protecting group. Examples of substituted alkyl groups include, but are not limited to, -CF 3
-CF
2
-CF
3 and other perfluoro and perhalo groups.
[0055] The term "alkenyl" refers to unsaturated aliphatic groups including straight-chain, branched-chain, cyclic groups, and combinations thereof, having the number of carbon atoms specified, or if no number is specified, having up to 12 carbon atoms, which contain at least one double bond Examples of alkenyl groups include, but are not limited to, -CH 2
-CH=CH-CH
3 and
-CH
2
-CH
2 -cyclohexenyl, there the ethyl group can be attached to the cyclohexenyl moiety at any available carbon valence. The term "alkynyl" refers to unsaturated aliphatic groups including straight-chain, branched-chain, cyclic 18 WO 02/10142 PCT/US01/24282 groups, and combinations thereof, having the number of carbon atoms specified, or if no number is specified, having up to 12 carbon atoms, which contain at least one triple bond "Hydrocarbon chain" or "hydrocarbyl" refers to any combination of straight-chain, branched-chain, or cyclic alkyl, alkenyl, or alkynyl groups, and any combination thereof. "Substituted alkenyl," "substituted alkynyl," and "substituted hydrocarbon chain" or "substituted hydrocarbyl" refer to the respective group substituted with one or more substituents, including, but not limited to, groups such as halogen, alkoxy, acyloxy, amino, hydroxyl, mercapto, carboxy, benzyloxy, phenyl, benzyl, cyano, nitro, thioalkoxy, carboxaldehyde, carboalkoxy and carboxamide, or a functionality that can be suitably blocked, if necessary for purposes of the invention, with a protecting group.
[0056] "Aryl" or "Ar" refers to an aromatic carbocyclic group having a single ring (including, but not limited to, groups such as phenyl) or multiple condensed rings (including, but not limited to, groups such as naphthyl or anthryl), and includes both unsubstituted and substituted aryl groups. Substituted aryls can be substituted with one or more substituents, including, but not limited to, groups such as alkyl, alkenyl, alkynyl, hydrocarbon chains, halogen, alkoxy, acyloxy, amino, hydroxyl, mercapto, carboxy, benzyloxy, phenyl, benzyl, cyano, nitro, thioalkoxy, carboxaldehyde, carboalkoxy and carboxamide, or a functionality that can be suitably blocked, if necessary for purposes of the invention, with a protecting group.
[0057] "Heteroalkyl," "heteroalkenyl," and "heteroalkynyl" refer to alkyl, alkenyl, and alkynyl groups, respectively, that contain the number of carbon atoms specified (or if no number is specified, having up to 12 carbon atoms) which contain one or more heteroatoms as part of the main, branched, or cyclic chains in the group. Heteroatoms include, but are not limited to, N, S, 0, and P; N and O are preferred. Heteroalkyl, heteroalkenyl, and heteroalkynyl groups may be attached to the remainder of the molecule either at a heteroatom (if a valence is available) or at a carbon atom. Examples ofheteroalkyl groups include, but are WO 02/10142 PCT/US01/24282 not limited to, groups such as -O-CH3, -CHz-O-CH 3
-CH
2
-CH
2
-O-CH
3
-S-CH
2
-CH
2
-CH
3
-CH
2
-CH(CH
3
)-S-CH
3
-CH
2
-CH
2
-NH-CH
2
-CH
2 -ethyl-6propylpiperidino, 2-ethylthiophenyl, and morpholino. Examples of heteroalkenyl groups include, but are not limited to, groups such as
-CH=CH-NH-CH(CH
3
)-CH
2 "Heteroaryl" or "HetAr" refers to an aromatic carbocyclic group having a single ring (including, but not limited to, examples such as pyridyl, thiophene, or furyl) or multiple condensed rings (including, but not limited to, examples such as imidazolyl, indolizinyl or benzothienyl) and having at least one hetero atom, including, but not limited to, heteroatoms such as N, O, P, or S, within the ring. Heteroalkyl, heteroalkenyl, heteroalkynyl and heteroaryl groups can be unsubstituted or substituted with one or more substituents, including, but not limited to, groups such as alkyl, alkenyl, alkynyl, benzyl, hydrocarbon chains, halogen, alkoxy, acyloxy, amino, hydroxyl, mercapto, carboxy, benzyloxy, phenyl, benzyl, cyano, nitro, thioalkoxy, carboxaldehyde, carboalkoxy and carboxamide, or a functionality that can be suitably blocked, if necessary for purposes of the invention, with a protecting group. Examples of such substituted heteroalkyl groups include, but are not limited to, piperazine, substituted at a nitrogen or carbon by a phenyl or benzyl group, and attached to the remainder of the molecule by any available valence on a carbon or nitrogen, -NH-S0 2 -phenyl, -NH-(C=0)O-alkyl, -NH-(C=0)O-alkyl-aryl, and -NH-(C=0)-alkyl. The heteroatom(s) as well as the carbon atoms of the group can be substituted. The heteroatom(s) can also be in oxidized form. Unless otherwise specified, heteroalkyl, heteroalkenyl, heteroalkynyl, and heteroaryl groups have between one and five heteroatoms and between one and twenty carbon atoms.
[0058] The term "alkylaryl" refers to an alkyl group having the number of carbon atoms designated, appended to one, two, or three aryl groups.
[0059] The term "alkoxy" as used herein refers to an alkyl, alkenyl, alkynyl, or hydrocarbon chain linked to an oxygen atom and having the number of carbon atoms specified, or if no number is specified, having up to 12 carbon WO 02/10142 PCT/US01/24282 atoms. Examples of alkoxy groups include, but are not limited to, groups such as methoxy, ethoxy, and t-butoxy.
[0060] The term "alkanoate" as used herein refers to an ionized carboxylic acid group, such as acetate (CH 3 propionate (CH3CH 2 and the like. "Alkyl alkanoate" refers to a carboxylic acid esterified with an alkoxy group, such as ethyl acetate (CH 3 C(=O)-O-CH2CH 3 "o-haloalkyl alkanoate" refers to an alkyl alkanoate bearing a halogen atom on the alkanoate carbon atom furthest from the carboxyl group; thus, ethyl o-bromo propionate refers to ethyl 3-bromopropionate, methyl o-chloro n-butanoate refers to methyl 4-chloro n-butanoate, etc.
[0061] The terms "halo" and "halogen" as used herein refer to Cl, Br, F or I substituents.
[0062] "Protecting group" refers to a chemical group that exhibits the following characteristics: 1) reacts selectively with the desired functionality in good yield to give a protected substrate that is stable to the projected reactions for which protection is desired; 2) is selectively removable from the protected substrate to yield the desired functionality; and 3) is removable in good yield by reagents compatible with the other functional group(s) present or generated in such projected reactions. Examples of suitable protecting groups can be found in Greene et al. (1991) Protective Groups in Organic Synthesis, 2nd Ed. (John Wiley Sons, Inc., New York). Preferred amino protecting groups include, but are not limited to, benzyloxycarbonyl (CBz), t-butyloxycarbonyl (Boc), tbutyldimethylsilyl (TBDIMS), 9-fluorenylmethyloxycarbonyl (Fmoc), tosyl, benzenesulfonyl, 2-pyridyl sulfonyl, or suitable photolabile protecting groups such as 6-nitroveratryloxy carbonyl (Nvoc), nitropiperonyl, pyrenylmethoxycarbonyl, nitrobenzyl, dimethyl dimethoxybenzil, 5-bromo-7nitroindolinyl, and the like. Preferred hydroxyl protecting groups include Fmoc, TBDIMS, photolabile protecting groups (such as nitroveratryl oxymethyl ether (Nvom)), Mom (methoxy methyl ether), and Mem (methoxy ethoxy methyl ether). Particularly preferred protecting groups include NPEOC (4- WO 02/10142 PCT/US01/24282 nitrophenethyloxycarbonyl) and NPEOM (4-nitrophenethyloxymethyloxycarbonyl).
[0063] The terms "peptide," "polypeptide", "polypeptide moiety", "protein", and the like are used interchangeably herein to refer to any polymer of amino acid residues of any length, polymers of two or more amino acids. The polymer can be linear or non-linear branched), it can comprise modified amino acids or amino acid analogs, and it can be interrupted by chemical moieties other than amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling or bioactive component. Amino acids include the twenty encoded amino acids (including proline, an imino acid), other alpha-amino acids, and other natural and artificial amino acids such as p-iodotyrosine and beta-alanine.
Cyclic polyamine analogs: Synthetic approach.
[0064] Cyclic polyamine derivatives that can affect the hydrolysis of ATP in vivo are constructed by condensing spermine (spm), its isomers and its higher and lower homologues, as well as spermidine (spd) and its isomers and higher and lower homologues, with an a, 3-unsaturated fatty acid chain (Scheme 1).
WO 02/10142 PCT/US01/24282
H
OH H2N
H
2 N N
H
R spm 0 H H H H
R
Scheme 1 [0065] Although Scheme 1 is very likely the pathway for biogenesis of cyclic polyamines pithecolobines and budmunchiamines), the practical synthetic approach follows a different route. The latter is depicted in Scheme 2 for several analogs of these series.
[0066] By reaction of ethyl bromoacetate 1 with triphenylphosphine the Wittig salt 2 was obtained. By condensation of 2 with aliphatic aldehydes 3a-3c following procedures of the Wittig reaction, the a, 3-unsaturated esters 4a-4c were obtained in ca. 90% yield. By reaction of 4a-4c with spermine (or a spermine analog), one equivalent of the base adds to the double bond by its primary amino group and the amino esters 5a-5e are obtained in ca. 40% yield.
Lactamization of 5a-5c to 6a-6c was achieved using antimony (III) ethoxide in 76% yield. Finally if N-methylation of the secondary amino residues of 6a-6c is desired, it can be achieved by a reductive alkylation reaction using formaldehyde and sodium cyanoborohydride to give 7a-7c. Yields for this reaction are ca. WO 02/10142 WO 0210142PCT/US01/24282 N-alkylation with homologues of formaldehyde will give the higher homologues of 7a-7c.
0 r Q Et a) Br
I
0 0 ?10Et
R
:'Ph 3 BC 3a R =propyl 2 3b R =mehyl 3c R pentyl b) 0 4a R propyl 4b R methyl 4c R =pentyl 0
C
QEt
H
N N H H H
R
5a R propyl 5b R =methyl 5c R pentyl 0
HH
N"
H H
R
e) Me I N
N
Vie Me
R
6a R propyl 6b R methyl 6c R =pentyl 7a R =propyl (Budmunchiamine A) 7b R methyl (Budmunchiamine, B) 7c R pentyl (Budmunchiamine C) Scheme 2 [00671 The conditions and reagents used in Scheme 2 are as follows: a) PPh 3 toluene, 2h, SOTC (94% yield); b) NaOEt, I O'C followed by warming to room temperature (88% yield); c) spermine, 40'C (43% yield); d) Sb(O~t) 3 benzene, reflux (76% yield); e) 1. formalin 37%, acetic acid, 0 0 C followed by warming to room temperature; 2. NaCNBH1 3 room temperature (93% yield).
24 WO 02/10142 PCT/US01/24282 [0068] In general, synthesis of compounds of the invention proceeds by reacting a haloalkyl alkanoate, preferably an co-haloalkyl alkanoate, with triphenylphosphine to give a phosphonium salt. The phosphonium salt is condensed with an aldehyde or ketone-containing compound, preferably an aldehyde-containing compound, to give an a,P-unsaturated alkenyl alkanoate following the general reaction protocol of the Wittig reaction. Addition of a polyamine containing at least two primary amino groups across the double bond yields a p-aminoalkyl alkanoate, where one of the primary amino groups has added to the double bond and the other amino group remains free. Condensation of the free amino group with the ester function gives the cyclic compound.
Derivatization of secondary amino groups, if present in the cycle, can then be carried out if desired. When amino groups ofpolyamines are connected by straight-chain alkyl groups, it can be readily appreciated that by varying the length of the alkyl groups and by varying the number of amino groups in the polyamine, different ring sizes can be constructed upon condensation of the polyamine to give the cyclic compound.
[0069] An alternate method to synthesize compounds of the invention is depicted in Scheme 3, where reagent 4c is as depicted in Scheme 2.
WO 02/10142 PCT/US01/24282 8 n
H
g N N NH EtOOC COOEt I9
N
H
v v v v v CH3 MeOH/HCI COOMe
CHH
N NH N H 2 6- CH3 considered a protected form of 1,3-diaminopropane; the methylene bridge H NH 11 CH3 Scheme 3 [0070] As can be readily appreciated, the synthesis following Scheme 3 utilizes a compound comprising a primary amino group and a hexahydropyrimidine moiety. The hexahydropyrimidine moiety can be considered a protected form of 1,3-diaminopropane; the methylene bridge between the two nitrogens in the hexahydropyrimidine ring is readily cleaved to yield the free amino groups. The portion of the molecule containing the free WO 02/10142 PCT/US01/24282 primary amino group is attached to one of the hexahydropyrimidine nitrogens; the primary amine can be linked to the hexahydropyrimidine nitrogen by any linker arm. Preferably the linker arm contains at least one carbon atom. The linker arm can be of the form -A 3
-(NY-A
2 where each A 2 (if present) and A 3 are independently selected from C 1 -Cs alkyl, where each Y is independently selected from H or C 1
-C
4 alkyl, and where j is 0, 1, 2, or 3; this compound is represented by the structural formula
H
2
N-A
3
-(NY-A
2 )j-N NH [0071] More preferably, the linker arm is -CH 2
CH
2
CH
2 as in compound 8 of Scheme 3. Hexahydropyrimidine 8 is readily prepared from spermidine and formalin (see Chantrapromma, K. et al., "The chemistry of naturally occurring polyamines. 2. A total synthesis of thermospermine," Tetr. Lett. (1980), 21(26):2475-6). Addition of the primary amino group across a bond converts the free primary amino group into a secondary amino group. In Scheme 3, the primary amino group adds across the alkene bond of an a,P3-unsaturated ester compound. The primidine ring can then be opened, releasing a second primary amino group, which can be condensed with the ester function of the molecule. Examples 14-16 detail the experimental conditions used in the synthesis of Scheme 3.
[0072] Using the synthetic methods described herein, the following compounds listed in Table 1 were synthesized.
WO 02/10142 WO 0210142PCT/US01/24282 Table 1 Synthesized Compounds 03 HCI 0
N
NH
I
NH *2 HCI
R
R= n-C 1 3
H
27 Me N N
H
G,,H7 N" N 4 HCI
G
1
H
7 I I Me Me WO 02/10142 PCT/US01/24282 SL-11239 NH 2 706 Me N N \C1327 5 HCI
C
13
H
27 N N Me Me Reduction of Compounds and Further Derivatization [0073] The compounds above can be readily reduced with hydride reagents, such as lithium aluminum hydride and other reducing agents known in the art, to convert the amide function into a secondary amine. For the cyclic polyamine compounds containing an amide group where the non-amide nitrogens, the amino groups, are alkylated, the amide group will be reduced to a secondary amino group, while the other nitrogens will be present as tertiary amino groups, and this difference can be exploited to perform further chemistry at the secondary amino group. The reduction is illustrated in Scheme 4, where Yalk indicates an alkyl group excluding hydrogen). (The reduction can, of course, be performed where the substituents on the non-amide nitrogens are hydrogen. In subsequent steps this will lead to derivatization of all (secondary) nitrogens in the compound, as opposed to the schemes outlined below, where only the nitrogen originally present as an amide was derivatized.) WO 02/10142 PCT/US01/24282 0 Yalk
H
R N N I I Yalk Yalk
LAH
R I I Yalk Yalk Scheme 4 [0074] The resulting secondary amine can then be reacted with a compound such as acrylonitrile to derivatize the secondary amine, as outlined in Scheme 5. Alternatively, the resulting secondary amine can then be reacted with a compound such as an co-haloalkyl nitrile, for example, but not limited to, where the alkyl group is a Ci-C 8 alkyl group and the halogen is iodo or bromo.
Alternatively, the secondary amine can be acylated with an acyl group 1 -C8 alkyl), or an amino acid or peptide can be coupled directly to the secondary amine. In the event of acylation with a group of the formula alkyl), the acyl group can be reduced with lithium aluminum hydride or other organometallic agents to form an alkyl group. An omega-cyano acyl group can also be introduced -C(=O)-Ci-C 8 alkyl-CN), which, upon reduction by lithium aluminum hydride, will yield a group of the form -CH 2
-C
1
C
8 alkyl-CH 2
NH
2 Alternatively, the secondary amine can be alkylated by alkyl halides in the presence of bases.
WO 02/10142 PCT/US01/24282 Yalk
H
R N N Yalk Yalk
"-'CN
CN
Yalk R N N R N N Yalk Yalk Scheme [0075] Reduction of the cyano group to a primary amino group is then conveniently performed by using Raney-Ni reagent under hydrogen.
[0076] The free primary amino group thus produced can be derivatized in various manners. One such manner is to use it as the starting point for peptide synthesis, by coupling the free acid group of an N-protected amino acid to the primary amino group of the aminoalkylcyclopropylamine. Various methods of coupling amino acids or peptides are known in the art. The polypeptides can be produced by recombinant methods single or fusion polypeptides) or by chemical synthesis. Polypeptides, especially shorter polypeptides up to about amino acids, are conveniently made by chemical synthesis, such as the Fmoc or Boc synthesis methods. See, for example, Atherton and Sheppard, Solid Phase WO 02/10142 PCT/US01/24282 Peptide Synthesis: A Practical Approach, New York: IRL Press, 1989; Stewart and Young: Solid-Phase Peptide Synthesis 2nd Ed., Rockford, Illinois: Pierce Chemical Co., 1984; and Jones, The Chemical Synthesis of Peptides, Oxford: Clarendon Press, 1994. The polypeptides can be produced by an automated polypeptide synthesizer employing the solid phase method, such as those sold by Perkin Elmer-Applied Biosystems, Foster City, California, or can be made in solution by methods known in the art.
[0077] Synthesis of peptides by repetitive coupling of amino acids to the primary amine of the aminoalkylated cyclic polyamine is readily performed by solution-phase peptide synthesis techniques, such as those extensively discussed in Bodanszky, Principles of Peptide Synthesis, 2nd Edition, Springer-Verlag: Berlin, 1993; Bodanszky, Peptide Chemistry: A Practical Textbook, 2nd edition, Springer-Verlag: Berlin, 1993, and Bodanszky, Bodanszky, The Practice of Peptide Synthesis, Springer-Verlag: Berlin, 1984, and other techniques well-known in the art. Peptides can also be attached to the cyclic polyamines by coupling of small protected peptide fragments, using the widelyknown techniques for fragment condensation methods in peptide synthesis.
Individual amino acids, such as leucine, can also be coupled to the cyclic polyamimes simply by stopping the peptide synthesis procedure after attachment of the first amino acid. Longer peptides, such as acetyl-Ser-Lys-Leu-Gln-Leu-, can be attached to the cyclic polyamines by either stepwise synthesis or fragment coupling methods.
[0078] By such peptide synthetic methods, the following compound: NH-Leu-GIn-Leu-Lys-Ser-acetyl Me N N C13H27 N N Me Me WO 02/10142 PCT/US01/24282 (SL-11243) was synthesized. The peptide sequence, from N-terminus to C-terminus of the peptide in SL-11243, is acetyl-Ser-Lys-Leu-Gln-Leu-, where the C-terminal leucine is coupled to the (formerly) primary amino group of the cyclopolyamine compound. Peptides of interest for use in the peptide-derivatized compounds described above include peptides which are substrates of prostate specific antigen (PSA) or cathepsin B. Peptides of length 25 amino acids or less, or 10 amino acids or less, can be used. Examples of such sequences cleaved by PSA are HSSKLQ, SKLQ-p-alanine,SKLQL, or SKLQ, with or without Nterminal protecting or capping groups such as Boc, Fmoc, acetyl, or other acyl capping groups, and with or without side-chain protecting groups (such as carbobenzyloxycarbonyl, Boc or Fmoc on the e-amino group of lysine).
[0079] Examples ofpolypeptides recognized and cleaved by cathepsin B include the peptide sequence Zi-P 2 where Z 1 is hydrogen, an aminoprotecting group, or an amino-capping group attached to the N-terminus of P 2 where P 2 is the N-terminal amino acid and Pi is the C-terminal amino acid; and where P 2 is a hydrophobic amino acid and PI is a basic or polar amino acid. In another embodiment, the peptide sequence is ZI-P 2 where Zi is hydrogen, an amino-protecting group, or an amino-capping group attached to the N-terminus of P 2
P
2 is a hydrophobic amino acid; P 1 is a basic or polar amino acid; and where Y is leucine, p-alanine, or a nonentity. In a further embodiment, Z 1 is a 4morpholinocarbonyl group. In yet another embodiment, P 2 is selected from the group consisting of leucine, isoleucine, valine, methionine, and phenylalanine; and Pi is selected from the group consisting of lysine, arginine, glutamine, asparagine, histidine and citrulline.
Utility of Cyclic Polyamines as Anti-neoplastic Agents.
[0080] To assess the utility of the subject compounds in the treatment of neoplastic cell growth, the ability of the compounds to inhibit the in vitro growth characteristics of several commonly used cancer models were studied. For instance, the subject polyamines induce cell growth inhibitions in several cultured WO 02/10142 PCT/US01/24282 human prostate tumor cell lines such as LnCap, DuPro, and PC-3 as determined by an accepted MTT assay (Table All three cell lines are sensitive to the cyclic polyamines, with ID 5 0 values ranging from 500 nM to 2,600 nM. The results with the DuPro cell line are given; these results are representative of the results with human prostate cell lines. The cyclic polyamines of the present invention have been shown to inhibit cell growth and to cause cell death in accepted in vitro test cultures of human prostate cancer cell lines as shown in Figs. 1-14. The figures are described in detail in the Example section below. The uptake of the cyclic polyamines by the DuPro cells and the resultant changes in the cellular polyamine levels are shown in Tables 3a and 3b.
[0081] The hydrolysis of ATP is believed to be one of the probable causes of cell kill. In a standardized method for measuring acid hydrolysis of ATP, a marked increase was observed in ATP hydrolysis in the presence of the cyclic polyamines (see Figs. 15-21) as compared to the lack of ATP hydrolysis in the presence of the naturally occurring linear polyamine spermine. The cyclic polyamines were also found to hydrolyze ATP in vivo in the cancer cells (Fig. 22- 24). The concentration of cyclic polyamines required to hydrolyze intracellular ATP in the cancer cells parallels the concentrations at which they produce cell kill (Figs. 6-14), lending support to the hypothesis that cell kill is due to intracellular ATP depletion. However, the invention is not to be construed as limited by any particular theory of biological or therapeutic activity.
Therapeutic use ofpolyamine analogs [0082] Polyamine analogs of the present invention are likely to be useful for treatment of a variety of diseases caused by uncontrolled proliferation of cells, including cancer, particularly prostate cancer and other cancer cell lines. The analogs are used to treat mammals, preferably humans. "Treating" a disease using a cyclic polyamine of the invention is defined as administering one or more cyclic polyamines of the invention, with or without additional therapeutic agents, in order to prevent, reduce, or eliminate either the disease or the symptoms of the disease, or to retard the progression of the disease or of symptoms of the disease.
34 WO 02/10142 PCT/US01/24282 "Therapeutic use" of the cyclic polyamines of the invention is defined as using one or more cyclic polyamines of the invention to treat a disease, as defined above.
[0083] In order to evaluate the efficacy of a particular novel cyclic polyamine for a particular medicinal application, the compounds can be first tested against appropriately chosen test cells in vitro. In a non-limiting example, polyamine analogs can be tested against tumor cells, for example, prostate tumor cells. Exemplary experiments can utilize cell lines capable of growing in culture as well as in vivo in athymic nude mice, such as LNCaP. Horoszewicz et al.
(1983) Cancer Res. 43:1809-1818. Culturing and treatment of carcinoma cell lines, cell cycle and cell death determinations based on flow cytometry; enzyme assays including ODC, SAMDC and SSAT activities; and high pressure liquid chromatography detection and quantitation of natural polyamines and polyamine analogs are described in the art, for example, Mi et al. (1998) Prostate 34:51-60; Kramer et al. (1997) Cancer Res. 57:5521-27; and Kramer et al. (1995) J Biol.
Chem. 270:2124-2132. Evaluations can also be made of the effects of the novel cyclic polyamine analog on cell growth and metabolism.
[0084] Analysis begins with IC 5 0 determinations based on dose-response curves ranging from 0.1 to 1000 ptM performed at 72 hr. From these studies, conditions can be defined which produce about 50% growth inhibition and used to: follow time-dependence of growth inhibition for up to 6 days, with particular attention to decreases in cell number, which may indicate drug-induced cell death; characterize analog effects on cell cycle progression and cell death using flow cytometry (analysis to be performed on attached and detached cells); examine analog effects on cellular metabolic parameters. Analog effects can be normalized to intracellular concentrations (by HPLC analysis), which also provide an indication of their relative ability to penetrate cells. Marked differences in analog uptake can be further characterized by studying analog ability to utilize and regulate the polyamine transporter, as assessed by competition studies using radiolabeled spermidine, as previously described in Mi WO 02/10142 PCT/US01/24282 et al. (1998). Cyclic polyamines could also enter the cells by a diffusion mechanism.
In vivo testing of cyclic polyamine analogs [0085] Analogs found to have potent anti-proliferative activity in vitro towards cultured carcinoma cells can be evaluated in in vivo model systems. The first goal is to determine the relative toxicity of the analogs in non-tumor-bearing animals, such as DBA/2 mice. Groups of three animals each can be injected intraperitoneally with increasing concentrations of an analog, beginning at, for example, 10 mg/kg. Toxicity as indicated by morbidity is closely monitored over the first 24 hr. A well-characterized polyamine analog, such as BE-333, can be used as an internal standard in these studies, since a data base has already been established regarding acute toxicity via a single dose treatment relative to chronic toxicity via a daily x 5 d schedule. Thus, in the case of new analogs, single dose toxicity relative to BE-333 is used to project the range of doses to be used on a daily x 5 d schedule.
[0086] After the highest tolerated dosage on a daily x 5 d schedule is deduced, antitumor activity is determined. Typically, tumors can be subcutaneously implanted into nude athymic mice by trocar and allowed to reach 100-200 mm 3 before initiating treatment by intraperitoneal injection daily x 5 d.
Most analogs can be given in a range between 10 and 200 mg/kg. Analogs can be evaluated at three treatment dosages with 10-15 animals per group (a minimum of three from each can be used for pharmacodynamic studies, described below).
Mice can be monitored and weighed twice weekly to determine tumor size and toxicity. Tumor size is determined by multi-directional measurement from which volume in mm 3 is calculated. Tumors can be followed until median tumor volume of each group reaches 1500 mm 3 20% of body weight), at which time the animals can be sacrificed. Although the initial anti-tumor studies focuses on a daily x 5 d schedule, constant infusion can be performed via Alzet pump delivery for 5 days since this schedule dramatically improves the anti-tumor activity of BE-333 against A549 human large cell hung carcinoma. Sharma et al. (1997) 36 WO 02/10142 PCT/US01/24282 Clin. Cancer Res. 3:1239-1244. In addition to assessing anti-tumor activity, free analog levels in tumor and normal tissues can be determined in test animals.
Methods of administration of cyclic polyamine analogs [0087] The polyamine analogs of the present invention can be administered to a mammalian, preferably human, subject via any route known in the art, including, but not limited to, those disclosed herein. Preferably administration of the novel polyamine analogs is intravenous. Other methods of administration include but are not limited to, oral, intrarterial, intratumoral, intramuscular, topical, inhalation, subcutaneous, intraperitoneal, gastrointestinal, and directly to a specific or affected organ. The novel polyamine analogs described herein are administratable in the form of tablets, pills, powder mixtures, capsules, granules, injectables, creams, solutions, suppositories, emulsions, dispersions, food premixes, and in other suitable forms. The compounds can also be administered in liposome formulations. The compounds can also be administered as prodrugs, where the prodrug undergoes transformation in the treated subject to a form which is therapeutically effective. Additional methods of administration are known in the art.
[0088] The pharmaceutical dosage form which contains the compounds described herein is conveniently admixed with a non-toxic pharmaceutical organic carrier or a non-toxic pharmaceutical inorganic carrier. Typical pharmaceuticallyacceptable carriers include, for example, mannitol, urea, dextrans, lactose, potato and maize starches, magnesium stearate, talc, vegetable oils, polyalkylene glycols, ethyl cellulose, poly(vinylpyrrolidone), calcium carbonate, ethyl oleate, isopropyl myristate, benzyl benzoate, sodium carbonate, gelatin, potassium carbonate, silicic acid, and other conventionally employed acceptable carriers. The pharmaceutical dosage form can also contain non-toxic auxiliary substances such as emulsifying, preserving, or wetting agents, and the like. A suitable carrier is one which does not cause an intolerable side effect, but which allows the novel cyclic polyamine analog(s) to retain its pharmacological activity in the body.
Formulations for parenteral and nonparenteral drug delivery are known in the art 37 WO 02/10142 PCT/US01/24282 and are set forth in Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing (1990). Solid forms, such as tablets, capsules and powders, can be fabricated using conventional tableting and capsule-filling machinery, which is well known in the art. Solid dosage forms, including tablets and capsules for oral administration in unit dose presentation form, can contain any number of additional non-active ingredients known to the art, including such conventional additives as excipients; dessicants; colorants; binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets can be coated according to methods well known in standard pharmaceutical practice. Liquid forms for ingestion can be formulated using known liquid carriers, including aqueous and non-aqueous carriers, suspensions, oil-in-water and/or water-in-oil emulsions, and the like.
Liquid formulations can also contain any number of additional non-active ingredients, including colorants, fragrance, flavorings, viscosity modifiers, preservatives, stabilizers, and the like. For parenteral administration, novel cyclic polyamine analogs can be administered as injectable dosages of a solution or suspension of the compound in a physiologically acceptable diluent or sterile liquid carrier such as water or oil, with or without additional surfactants or adjuvants. An illustrative list of carrier oils would include animal and vegetable oils (peanut oil, soy bean oil), petroleum-derived oils (mineral oil), and synthetic oils. In general, for injectable unit doses, water, saline, aqueous dextrose and related sugar solutions, and ethanol and glycol solutions such as propylene glycol or polyethylene glycol are preferred liquid carriers. The pharmaceutical unit dosage chosen is preferably fabricated and administered to provide a final concentration of drug at the point of contact with the cancer cell of from 1 pM to mM. More preferred is a concentration of from 1 to 100 pM. The optimal effective concentration of novel cyclic polyamine analogs can be determined empirically and will depend on the type and severity of the disease, route of 38 WO 02/10142 PCT/US01/24282 administration, disease progression and health and mass or body area of the patient. Such determinations are within the skill of one in the art. Cyclic polyamine analogs can be administered as the sole active ingredient, or can be administered in combination with another active ingredient, including, but not limited to, cytotoxic agents, antibiotics, antimetabolites, nitrosourea, vinca alkaloids, polypeptides, antibodies, cytokines, etc.
EXAMPLES
Chemical Synthesis Examples [0089] The following examples are illustrative of the manufacture of several compounds according to the present invention, and are not intended to limit the invention disclosed and claimed herein in any fashion. The Examples are included herein solely to aid in a more complete understanding of the present invention. Reference numerals 1-11 refer to compounds in Reaction Schemes 2 and 3 described above. Reference numbers 12-14 refer to compounds shown in the Examples and so labeled.
[0090] All commercially available reagents were used without further purification. All reactions were followed by TLC (silica gel F 264 precoated, Merck); column chromatography was carried out with silica gel (Merck 0.040-0.063 mesh). The detection was performed either with UV light or the following reagents: KMnO 4 soln. (1:1 mixture of 1% aq. KMnO 4 soln. and 5% aq.
Na 2
CO
3 soln.); Schlittler reagent (iodine platinate) (1 g H 2 PtCI 6 in 6 ml H20, ml 1N HCI and 25.5 g KI in 225 ml H 2 0 diluted to 1 L) for amides and amines.
IR measurements are presented in units of [cm' i and were recorded on a Perkin-Elmer 781 instrument. NMR spectra were recorded on Bruker-300 or Bruker AMX-600 instruments with 5 in ppm and using the appropriate solvent as internal standard. MS spectra were generated on Finnigan MAT SSO 700 or Finnigan MAT 90 instruments using chemical ionization (CI) with NH 3 and WO 02/10142 WO 0210142PCT/US01/24282 electron impact (El; 70 eV), and on a Finnigan TSQ 700 instrument using electrospray ionisation (ESI).
[00911 Numerals included in the structure drawings denote atom numbers for spectroscopic data which are not otherwise identified; the numbers 1 and 2 for the compound 2 in Example 1 identify carbons 1 and 2 for the carbon nuclear magnetic resonance assignments.
Example 1 (Ethoxycarbonylmnethyl)triphenylphosphonium bromide 0 1 r20 QEt PPh 3
BC
[00921 To a suspension of 22 g (84 nimol) triphenyiphosphine in 200 ml toluene were added 14 g (84 nunol) ethyl bromoacetate. The mixture was heated 2 h at 80'C and stirred overnight at room temp. It was filtered, washed with toluene and the precipitated phosphoniumn bromide was dried 15 h at 1 0- mbar to give 34 g 2 as colorless crystals. For analytical purposes, 300 mg were recrystallized from (CHCl 3 /hexane 1: 2) to give 292 mg.
Rf (CHC1 3 /MeOH 9: 1, UV 25 4 0.16.
mnp.: 150-1550 (CHCl 3 Ihexane 1 IR (CHC1 3 3360w, 2915s. 2705w, 2400w, 1725s, 1585w, 1335mi, 1370w, 1305m, 121GOm, 111 lOs, 1020w, 995w, 845w, 660m, 620w.
'H-NMR (CDCI,): 7.93-7.3 3 (in, 15 arom. 5.47 J= 13.8, H 2 4.02 J= 7.1, OCH 2
CH
3 1.05 J= 7.2, OCH 2
CH
3 1 3 C-NMR (CDCl 3 ):164.2 135.1, 133.9, 133.7, 130.2,130.1 arom. 118.4, 117.2, (2s, 3 arom. 62.7 OCII 2
CH
3 33.4, 32.7 (2t, 13.6 OCII 2
UH
3 ESI-MS: 349 WO 02/10142 WO 0210142PCT/US01/24282 Example 2 Ethyl 2-Tetradecenoate (4a).
0 1 Et I L3 13 [00931 To a soin. of NaOEt prepared from 575 mg (25 mmol) of Na. and 100 nil EtOH were added portionwise at 10' 10.7 g (25 mmol) 2 and stirred 1 h at room temp. After the addition of 4.3 7 g (23.75 mmol) laurinaldehyde 3 in 20 ml
CH
2 Cl 2 and overnight stirring at room temp., the mixture was evaporated and the' crude product filtered through 50 g SiO 2 (Et 2 Olhexane 1:2) to afford 5.1 g (88%) 4a as an mixture 2: For analytical purpose, 450 mg of 4a were purified by chromatography (Et 2 O/hexane 2:98) to give 140 g (3 1 of the (Z) isomer and 285 mg of the isomer as a colorless oils.
Rf (Et 2 O/hexane 3:97, KPM): 0.67 isomer, 0.47 isomer.
JR (CHCl 3 2920vs, 2850s, 1720s, 1640m, 1455m, 1415m, 1360m, 1295w, 123 Sm, I11 75s, I11115s, 1 030m, 925w, 820mn, 660m, 620w.
'IH-NMR (CDC1 3 6.21 (dt, J= 11.5, 5.7, 5.75 J= 11.5, 4.16 J 7.2, OCH 2
CH
3 2.63 J 7.3, H 2 1.41 J =6.3,
H
2 1.30-1.25 (in, 8 GCl 2
OCH
2
CH
3 0.88 6.9, H 3 C(14)).
1 3 C-NMR (CDC1 3 166.6 150.5 119.5 101.6 59.6 OCH 2
CH
3 34.3 31.8 29.6 29.5, 29.4, 29.3, 29.2, 28.9, 23.4 (6t, 6 22.5 14.1 OCH 2
GH
3 13.9 (q, C(14)).
'H-NMR (CDC 3 6.94 (dt, J 15.6, 7.0, 5. 80 J 15.6, 4.17 J 7. 1, OCH 2
CH
3 2.19 J1, 7.0, H 2 1.44 Qt, J 7.2,
H
2 1.32-1.26 (in, 8 CH 2
OCH
2
CH
3 0.87 Qt, 6.9, H 3 C(14)).
WO 02/10142 WO 0210142PCT/US01/24282 3 0-NMR (CDC1 3 166.8 149.9 121.2 60.1 OCH 2
CH
3 32.2 31.9 29.6 29.5, 29.4, 29.3, 29.1, 28.1. 23.5 (6t, 6C); 22.7 0(1 14.3 14.1 OCH 2
CII
3 EI-MS: 254 209 157 127 113 (27), 99 81 (3 67 55 43 (100).
Example 3 Ethyl 1 6-Amino-3-undecyl-4, 8, 13-fria-zahexadecanoate (5 a).
0 [00941 A soin. of 3.49 g (13.7 mmol) 4a in 20 ml EtOH was added over a period of 30 min to a stinecd soin. of 2.77 g (13.7 nimol) spermine in 150 ml EtOll and the mixture heated for 3 d at 400. Evaporation of the solvent and chromatography of the residue over 100 g SiO 2
(CH
2 C1 2 /EtOHINH 4 OH 6:3: 1) gave 2.5 g of 5a as a colorless oil.
Rf (CHC1 3 /MeOH/25 aq. NH40OH 7:4: 1, Scizlittler): 0.26.
IR (CHC1 3 2920vs, 2850vs, 1720vs, 1580w, 1460s, 1370s, 1300m, 11 80m, 11i1s, 1025m, 920m, 885m, 845m, 655s, 620w.
'H-NMR (CDCI 3 4.12 J 7. 1, OCH 2
CH
3 2.92 (quint, J 6.4, 2.78 J= 6.8, 1120(16)); 2.69 J= 7.0, 1120(9), H 2 2.45 J= 6.8, H 2 1120(7), 1120(14)); 2.38 J= 6.3, 1120(2)); 2.19 (br. s, NE, Nil 2 1.66 (quint, J= 6.9, 112C(6), H2C(15)); 1.54 (quint, J=7.1, 1120(10), H 2 C(1 1.28-1.23 (in, 10OCH 2 0CH 2
CH
3 0.88 7.0, H 3 C(l1)).
13 C-NMR (CD1 3 172.5 60. 0 OCJ{ 2
CH
3 54.7 49.7 48.2 47.6 45.2 40.3 39.1 (t, 34.3 33.5 31.7 30.3, 29.5, 29.4 (3t, 6 29.1 27.7 25.6 0(1 22.4 14.0 (q,
OCH
2 0H 3 13.9 0(11l')).
WO 02/10142 WO 0210142PCT/US01/24282 ESI-MS: 457 (28, 229 (100, Example 4 4-Undecyl- 1, 5, 9, 14-tetraazacycloheptadecan-2 -one (6a).
0 17 13 2 N
N
H H 4 9 H H [00951 A solution of 1.3 g (2.85 mmol) 5a in 180 ml dry benzene was heated over molecular sieves for 2 h under reflux. After cooling to room temp., 0 mg (3.7 mmol) antimony(III) ethoxide in 10 ml benzene was added under an argon atmosphere and the mixture was stirred for 16 h under reflux. The mixture was cooled at 100, quenched with EtOH and evaporated. The residue was purified by chromatography (50 g SiO 2
CH
2 ClJ/EtOH/NII 4 OH 15:4:1) to give 915 mg of 6a as a colorless oil.
RJ(CHC1 3 /MeOHI25% aq. NH 4 0H 7:4: 1, Schlittler): 0.47.
IR (CHCl 3 3240w, 2920vs, 2850vs, 1640s, 1520m, 1460m, 1370m, 1220m, 112Gm, 1045w, 925w, 805m, 66Gm, 620w.
'H-NMR (CDCl 3 8.44 (br. s, NH), 3.37 J= 7.7, H 2 2.83 (quint, J= 7.0, 2.76-2.72 (in, H 2
H
2 2.68 J= 5.4, H 2 C(l0),
H
2 C(1 H 2 2.37 (dd, J= 15.2. 3.3, HaC(3)); 2.25 (br. s, NH); 2.14 (dd, J 15.3, 7.2, HbC(3)); 1.67 (quint, J= 6.1, H 2
H
2 1.59 (quint, J=
H
2 C(l H 2 1.41-1.25 (in, lO CH 2 0.88 J= 7.0, H 3 C(Il1)).
1 3 C-NMR (CDCI 3 172.2 55.4 48.4 48.2 (t, 48.0 47.3 45.7 40.3 37.6 (Q, C(1 34.0 31.7 29.6, 29.4 (2t, 6 29.2 28. 8 (t, 26.7 26.6 25.7 22.5 13.9 (q, WO 02/10142 WO 0210142PCT/US01/24282 ESI-MS: 411 (44, [MU+ 206 (100, [M Example 5,9, 14-Trimethyl-4-undecyl-1, 5,9, 14-tetraazacycloheptadecan-2-one (Budmunchiamine A) (7a).
0 17 Me 1 N 1
H
4 L9 Me Me [00961 A soin. of 90, mg (0.21 mmol) 6a and 3 ml formalin (3 in 10 ml AcOH was stirred at After 7 min, 250 mg (4 mmol) of NaCNBH 3 in 1 ml MeOH were added and the mixture was stirred overnight at room temp. After cooling to 50, the mixture was quenched with 2N HCl and the org. solvent evaporated. The residue was dissolved in 5 ml sat. aq. K 2 C0 3 soin., extracted with CH 2 C1 2 and dried over Na 2
SO
4 After evaporation of the solvent and chromatography of the residue (10 g SiO 2 CHCl 3 /MeOH/25% aq. NHJ 4 0H 90:10:0.7) 78 mg of 7a was obtained as a colorless oil.
Rf (CHC1 3 /MeOH/25% aq. NH 4 0H 85:14:1, Schlittler): 0.41.
IR (CHiC1 3 3420m, 2920vs, 2850vs, 2800s, 1640vs, 1520s, 1460s, 1370mn, 1230m, 1135m, 1050m, 920w, 845w, 680w, 655m.
'H-NMR (CDCI 3 8.55 (br. s, NH); 3.32 (dt, J= 6.6, 6.8, H 2 2.84 (quint, J= 4.7, 2.62 (dt, J= 12.3, 7.0, HaC(6)); 2.49-2.41 (in, H 2 C(13)); 2.41 (in, HbC(6)); 2.39 (in, 11 2 2.41-2.32 (mn, H 2 2.44-2.34 (in,
H
2 C(1 2.37 (in, HaC(3)); 2.24 (dd, J 6.2, 1.6, HbC(3)); 2.27 H 3 CN(9)); 2.19 H 3 CN(14), H 3 1.67 (quint, J= 6.5, 11 2 1.64 (quint, J= 6.4, 11 2 1.52 (quint, J= 6.7, H 2 C(1 H 2 1.30-1.17 (mn, 10 CH 2 0.88 J 6.9, H3C(1l')).
WO 02/10142 WO 0210142PCT/US01/24282 1 3 C-NVR (CDC1 3 172.5 61.1 56.3 56.2(Q, C(1 5 5.8 C(1 54.5 (t 51.5 42. 8 FI 3 42.3 (q,
H
3 CN(14)); 37.6 37.0 35.1 H 3 31.8 Qr, 29.7, 29.6, 29.5, 29.4, 29.2 (51, 6 27.5 (Q 27.3 27.1 26.0 24.4 23.3 (t 22.5 C(101)); 13.9 ESI-MS: 453 (100, 227 (80, 212+).
EI-MS: 452 (40, 437 (28, CH 3 380 366 295 273 243 238 226 212 200 186 169 149 127 112 100 98 86 84 (100), 70 58 49 43 (69).
Example 6 Ethyl 2-Dodecenoate (4b).
0 1OEt I 3 10097] Analogous to Example 2: From 1.7 g (74 mmol) of Na, 32 g (74 inmol) of 2 and 10.82 g (69.37 mmol) of caprinaldehyde 3b in 200 ml EtOH, 14.1 g 4b as an mixture 2: 1) was obtained after workup as a colorless oil. For analytical purpose, 320 mg of 4b were purified by chromatography (Et 2 O/hexane 2:98) to give 104 mg of isomer and 205 mg of (E) isomer as a colorless oils.
Rf (Et 2 O/hexane 3:97, KPM): 0.68 isomer, 0.47 isomer.
IR (CHC1 3 2920vs, 2850vs, 171lOvs, 1650s, 1460m, 1370s, 1310Os, 1275s, 1 170m, 1 130m, 1035m, 980m, 825w, 660w, 620w.
WO 02/10142 WO 0210142PCT/US01/24282 'H-NMR (CDCl 3 6.22 (dt, J= 11.5, 7.5, 5.74 (dt, J= 11.5, 1.7, 4.16 J= 7. 1, OCH 2
CH
3 2.63 J 7.3, H 2 1.43 J= 6.3, 11 2 1.30-1.25 (in, 6 CH 2
OCH
2
CH
3 0.87 J= 7.0, H 3 C(12)).
13 C-NMR (CDC1 3 166.4 150.4 119.5 59.6 Qt, 0C1 2 C1 3 31.7 29.4 29.3, Qt, 29.1, 29.0, 28.9, (3t, 4 22.5 14.1 13.9 OCH 2
CH
3 'H-NMR (CDCL 3 6.95 (dt, J= 15.6, 7.0, 5.80 (dt, J= 15.6, 1.6, 4.16 J= 7.2, OCH 2
CH
3 2.18 J= 7. 1, H 2 1.45 J 7.2, H 2 1.32-1.26 (in, 6 CH 2
OCH
2
CH
3 0.88 6.9, H 3 C(12)).
13 C-NMR (CDCL 3 166.6 149.3 121.1 59.9 OCH 2
CH
3 32.0 31.7 29.3, 29.2, 29.1, 29. 0, 27.9 (4t, 4 22.5 C(1 14.1 C(1 13.9 0CH 2 C11 3 CI-MS: 227 (76, 226 (52, NH 4
H
2 181 (52, [M- 138 (16),127 (100), 144 99 88 81 55 43 (41).
Example 7 Ethyl 16-Amino-3-nonyl-4-8, 13-triazahexadecanoate 0 1OEt 7 Hi H H 12 16 [00981 Analogous to Example 3: From 6.46 g (32 mmol) of spermine and 7.23 g (32 mmol) of Ub in 500 mal EtOH, 5.2 g of 5b were obtained after workup as a colorless oil.
Rf (CHCI 3 /MeOW25% aq. NH 4 0H 7:4:1, Schlittler: 0.25.
JR (CHCI 3 ):2920vs, 2850s, 1720m, 1600w, 15l10m, 1370w, 1300w, 1220w, 11 15m, 1025w, 925w, 840w, 660m, 620w.
'H-NMR (CDC1 3 4.15 J 7.2, OCH 2
CH
3 2.92 (quint, J 6.2, 2.77 J 6.8, H 2 C(1 2.75-2.70 (in, H 2
H
2 C(1 2.69-2.67 (mn,
H
2 2.62 (in, H 2
H
2 2.38 J= 6.2, H 2 1.98 (br. s, NH, WO 02/10142 WO 0210142PCT/US01/24282
NH
2 1.64 (quint, J= 6.9, 11 2
H
2 1.52 (quint, J= 6.4, H 2 C(1 0), fl 2 C(1 1.28-1.23 (in, 8 CIT 2
OCH
2
CH
3 ):0.88 6.5, H 3 3 C-NMR (CDCI 3 172.5 60.0 Qi, OCH 2
CH
3 54.7 49.6 48.2 47.6 45.2 40.3 39.1 (t, 34.2 33.5 31.7 30.2, 29.6, 29.5, 29.4 (4t, 4C); 29.1 27.6 25.6 C(1 22.5 14.1 (q,
OCH
2 CH3): 13.9 ESI-MS: 429 (43, 215 (100, Example 8 4-Nonyt-!, 5,9, 14-tetraazacycloheptadecan-2-one (6b).
0 17 13 H H '1 9 N N H H 91 [00991 Analogous to Example 4: From 4.2 g (9.8 nimol) 5b and 3 g (11.7 mmol) antimony(III) ethoxide in 190 ml benzene, 2.85 g of 6b were obtained after workup as a colorless oil.
RA(CHCl 3 /M\eOHI25% aq. NH 4 0HI 7:4: 1, Schlittler: 0.46.
IR (CHC1 3 2920vs, 2850vs, 1640vs, 1520mi, 1460n?, 1570w, 1220m, 11l2Oi, 1050w, 925w, 805n, 660m, 620w.
'H-NMR (CDC1 3 8.47 (br. s, NH); 3.36 (dt, J= 7.1, 6.1, H 2 2.83 (quint, J 6.6, 2.78-2.76 (mn, H 2
H
2 C(1 2.74-2.72 (in, H 2 2.69-2.66 (mn, 11 2 C(13), H 2 2.37 (dd,J= 15.2, 3.4, HaC(3)); 2.14 (dd, J= 15.2, 7.8, HbC(3)); 2.06 (br. s, NJ-I); 1.67 (quint, J= 6.2, H 2
H
2 1.59 (quint, J= 5.6, H- 2 C(1 H 2 1.48-1.32 (mn, H 2 1.25 (mn, 8 Cl-I 2 0.88 Qt, J= 6.4, H 3 C(1 l1)).
WO 02/10142 WO 0210142PCT/US01/24282 3 C-NMR (CDCI,);172.3 55.7 48.6 48.4 (t, 48.2 47.6 Qt, 45.9 Qt, 40.4 Qt, 37.8 C(17)); 34.1 31.8 Qt, 29.8, 29.7, 29.6, 29.3 (4t, 4 29.3 Qt, 29.0 C(1 26.8 C(1 25.9 22.6 14.1 C(11l)).
ESI-MS: 383 1 Example 9 5,9,1 4-Trimethyl-4-nony-1, 5,9, 14-tetraazacycloheptadecan-2-one (Budmunchiamine B) (7b).
0 17 Me 13 N N
H
49 ~Me Me 9, [0100] Analogous to Example 5: From 70 mg 18 mmol) of 6b, 3 ml of formalin and 200 mg (3.2 mmol) NaCNBH 3 in 8 ml AcOH, 62 mg of 7b were obtained after workup as a colorless oil.
Rf(CHC 3 /MeOHI25% aq. NH 4 0H 85:14: 1, Schiitler: 0.40.
IR (CHClj): 2920vs, 2850s, 2800m, 1640s, 1520m, 1455m, 1370w, 1235mn, 1130w, 1050w, 1005w, 925w, 800w, 660w, 620w.
'H-NMR (CD1 3 8.52 (br. s, NH); 3.31 (dt, J 6.9, 6.4, H 2 C(1 2.84 (quint, J= 4.6, 110(4)); 2.62 (dt, J= 12.4, 7.0, HaC(6)); 2.50-2.42 1120(13)); 2.41 (in, HbC(6)); 2.37 (in, 1120(8)); 2.42-2.33 (mn, H 2 2.44-2.35 (in, 1120(15)); 2.37 (in, HaO(3)); 2.24 J= 4.8, HbC(3)); 2.27 H 3 2.20 (s,
H
3 CN(14), H 3 1.65 (quint, J= 6.9, H 2 1.54 (quint, J= 6.8, 1120(1 H 2 1.30-1.17 (mn, 8 C14 2 0.88 7.0, H 3 13 CNMR 172.5 61.1 56.3 56.1 (t, 55.6 54.4 51.3 42.5 H 3 42.2 (q,
H
3 CN(14)); 37.5 t, 37.1 35.3 H 3 31.7 29.6, WO 02/10142 WO 0210142PCT/US01/24282 29.5, 29.4, 29.1 (4t, 4 27.4 C(1 27.3 27.1 25.5 (t, 24.2 C(1 23.2 C(1 22.5 13.9 C(91)).
ESI-MS: 425 (52, 213 (100, ET-MS: 424 (51, 0 409 (28, CH 3 352 338 297 281 224 212 210 198 184 169 155 112 100 98 86 84 (100), 72 70 58 57 43 (29).
Example Ethyl 2-Hexadecenoate (4c).
0 1OEt I L3 10101] Analogous to Example 2: From 1. 17 g (51 minol) of Na, 21.9 g (51 Mmol) of 2 and 10 g (47.1 mmol) of myristinaldehyde 3c in 200 ml EtOH, 11.6 g 4c as an mixture (z 2: 1) were obtained after workup as a colorless oil. For analytical purpose, 350mig of 4c were purified by chromatography.
(Et 2 O/hexane 2:98) to give 109 mg (3 1 of isomer and 230 mg of (E) isomer as a colorless oils.
Rj(Et 2 O/hexane 3:97, KPAI): 0.67 isomer, 0.47 isomer.
IR (CHCl 3 2920vs, 2850vs, 1710vs, 1650s, 1460s, 1365m, 1275s, 1180s, 1 125n, 1095w, 1035i, 980m, 925w, 610w, 660w, 620w.
'H-NMR (CDC 3 (Z)j6.22 (dJ= 11.4, 7.5, 5.73 (dt, J= 11.5, 1.6, 4.18 J 7. 1, OCH 2
CH
3 2.62 J 7.3, H 2 1.43 (quint, J
H-
2 1.32-1.25 (in, 10 CH 2
OCH
2
CH
3 0.88 J= 7.0, H 3 C(16)).
3 C-NMR (CDCI 3 169.3 150.4 119.5 59.6 OCH 2
CH
3 32.0 31.8 29.5, 29.4,29.3,29.2, WO 02/10142 WO 0210142PCT/US01/24282 29.1, 29.0, 28.9, 27.9 (7t, 8 C) 22.5 C(1 14.1 C(1 13.9 (q,
OCII
2
CH
3 'H-NMR (CDC1 3 6.95 (cdt.J= 15.6, 7.0, 5.80 (cdtJ= 15.6, 1.6, 4.1t8 J 7. 1, OCH 2
CH
3 2.18 J H 2 1.43 (quint, J
H
2 1.32-1.25 (in, 10 CH 2
OCH
2
CH
3 0.88 J= 7.0, H 3 C(16)).
3 CNMR (CDC1 3 166.6 149.3 (di, 121.1 59.9 OCH 2
CH
3 32.0 31.8 29.5, 29.4,29.3,29.2, 29.1, 29.0, 28.9, 27.9 (7t, 8 22.5 14.1 13.9 (q,
OCH
2
CH
3 CI-MS: 283 282 (16, NH 4
H
2 237 (37, [M- 194 127 114 101 99 88 81 69 57 43 41 (100).
Example I11 Ethyl] 6-Amino-3-tridecyl-4, 8, 13-triazahexadecanoate [01021 Analogous to Example 3: From 4.3 g (21.28 mmol) of spennine and 6 g (21.28 mnmol) of 4c in 900 ml EtOH, 4.25 g of 5c were obtained after workup as a colorless oil.
RfiCHCl 3 /MeOH/25% aq. NH 4 0H 7:4:1, Schlittler): 0.27.
JR (CH-CI 3 2920vs, 2850s, 1720s, 1600w, 1460m, 1370m, 1220m, 1 180m, I1I15m, 1025w, 925w, 805m, 660m, 620w.
'H-NMR (CDC1 3 4.13 J= 7.2, OCH 2
CT{
3 2.92 (quint, J= 6.2, 2.76 J= 6.8, H 2 2.69-2.68 (in, H 2
H
2 2.64 (in,
H
2 2.62-2.60 (mn, H 2
H
2 2.38 (dI, J= 6.3, HzC(2)); 1.63 (quint,]J 7.0, H 2
H
2 1.51-1.45 (in, H 2 C(10), H 2 C(1 NI-1, NH 2 1.32-1.25 (in, 12 CH 2
OCH
2
CH
3 0.88 Qt, J= 7.0, H 3 WO 02/10142 WO 0210142PCT/US01/24282 13 C-NMR (CDC1 3 172.7 60.2 OCH 2
CH
3 54.9 49.9 48.5 47.8 45.4 40.6 39.3 (t, 34.2 33.5 31.9 30.6, 29.8, 29.7, 29.6, 29.3, 29.2 (6t, 8 27.9 25.8 22.6 14.2 (q,
QCH
2
CH
3 14.1 C( ESI-MS: 485 (20, 243 (100, Example 12 4-Tridecyl-], 5,9, 14-tetraazacycloheptadecan-2-one (6c).
0 17 13 H H 4 9 1' N N H H 12' [01031 Analogous to Example 4: From 1.7 g (3.5 mmol) of 5c and 1. 16 g (4.55 mmol) of antimony(III) ethoxide in 180 ml benzene, 1.2 g of 6c were obtained after workup as a colorless oil.
RJ(CHCl 3 /MeOH!25% aq. N1H 4 0H 7:4: 1, Schlittler): 0.49.
IR (CHCI 3 3300m, 2920vs, 2850vs, 1640s, 1520m, 1460s, 1370m, 1220mn, 11 15m, 1045w, 925w, 805w, 660m, 620w.
'H-NMR (CDC1 3 8.43 (br. s, NUl); 3.37 J 5.6, H 2 C(1 2.86-2.83 (in, 2.77-2.74 (in, H 2
H
2 2.72-2.78 (in, H 2 2.68-2.66
H
2 C(13), H 2 2.37 (dd, J= 15.2, 2.4, HaC(3)); 2.32 (br. s, 2.14 (dd, J= 15.3, 7.8, IHbC(3)); 1.67 (quint, J= 6.0, H 2
H
2 1.59-1.50 (mn,
H
2 C(1 H 2 1.25 (in, 12 CH 2 0.88 J= 6.6, H 3 3 C-NMR (CDCl 3 172.2 55.6 48.6 48.2 (t, 48.3 47.5 45.9 40.3 37.8 C(17)); 34.0 31.8 29.7, 29.6, 29.3 (4t, 4C); 29.3 29.1 (t, C(1 26.7 C(l 25.9 C(1 22.6 C(1 14.0 (C(1 WO 02/10142 WO 0210142PCT/US01/24282 ESI-MS: 439 Example 13 9, 14-Trimethyl-4-tridecyl-1, 5, 9, 14-tetraazacycloheptadecan-2 -one (Budmunchiamine C) (7c).
0 17 Me 13 2 1
H
4
NN
NMe
M
9, 101041 Analogous to Example 5: From 77 mg (0.2 mmol) of 6c, 3 ml of formalin and 200 mg (3.2 mmol) of NaCNBH 3 in 8 ml AcOH, 65 mg (8 of 7c were obtained after workup as a colorless oil.
RI(CHCI
3 /MeOH-/25% aq. NH 4 0H 85:14: 1, Schlitdler): 0.42.
LR (CHCI 3 3420s, 2920vs, 2850s, 2800s, 1640s, 1520m, 1460s, 1370s, 1230mn, 1135m, 1050m, 920s, 840w, 670w, 650m.
1 1r-NMR (CDCl 3 8.50 (br. s, NH); 3.30 (dt, J=6.6, 6.8 CH 2 2.80 (quint, J=4.5, 2.60 (dt, J=12.3, 7.0, HaC(6)); 2.50-2.40 (in, CH 2 2.38 (in, HbC(6)); 2.37 (in, CH 2 2.40-2.30 (in, CH 2 2.44-2.34 (in, CH 2 2.35 (in, HaC(3)); 2.21 (dd, J=6.2, 1.6 HbC(3)); 2.20 IT 3 2.15 (s,
H
3 CN(14), H 3 1.67 (quint, J=6.5, H1 2 1.64 (quint, J=6.4, CH 2 1.50 (quint, J=6.7, CH 2 (1 CH 2 1.30-1.17 (in, CH 2 0.9 J=6.9,
CH
3 (1 13 CNMR (CDCI 3 ):172.5 61.0 (di, 56.3 56.1 (t, 55.5 54.5 51.0 43.0 CH 3 42.5 (q,
CH
3 37.6 37.1 35.0 CH 3 32.0 29.8, 29.6, 29.5, 29.4, 29.3 (5t, 8 27.5 27.3 27.1 25.9 24.3 23.2 22.5 13.9 WO 02/10142 WO 0210142PCT/US01/24282 ESI-MS: 503 481 (100, 11+).
EI-MS: 481 (18 480 (68 465 (37 CH 3 408 394 339 297 266 254 240 238 226 169 155 112 100 98 86 84 (100), 72 58 43 Example 14 I'-(4)-((3-Ethoxycarbonyl-J-tridecyl)ethyl)aminobutyliexahydropyrinidi ne 101051 A solution of ethyl 2-hexadecenoate-(4c, 2.82 g, 10 inmol) and N-(4-amninobutyl)hexahydropyrimidine 1.57 g, 10 mmol; see McManis, J.S., Ganem, I. Org. Chem. (1980), 45: 2042 and U.S. Pat. No. 5,869,734) in 400 ml of abs. EtOH was stirred for 4 days at 400. After evaporation the residue was purified by column chromatography (SiO 2
CH
2
CJ
2 /NeOH/25% aq. NH1 4 0H 100: 10: 1) to give 1.21 g of 9 as a colorless oil.
Rf 0.44 (CH 2
CI
2 /MeOH/25% aq. NH 4 OH 40:6:1).
1'H-NMR: 4.13 OCH1 2 3.48 N-C11 2 2.92 (in, CH); 2.80 CH 2 2.59 (in, 2 ClI 2 2.41 CH 2 CO); 2.25 (in, CT- 2 1.45-1.70 (in, 10 H, 4 CH 2 +2 NI-I); 1.15-1.35 (in, 11 CI-I 2 0.98 (in, 2 C11 3 CI-MS: 440 WO 02/10142 WO 0210142PCT/US01/24282 Example Methyl 12-Aiino-3-tridecyl-4, 9-diazadodecanoate [01061 A solution of 9 (663 mg, 1.51 mniol) in 50 ml of MeOH saturated with dry HCl gas was refluxed for 10 h. After evaporation the residue was dried in vacuum and converted to free base by column chromatography (SiC) 2
CH
2 Cl 2 /EtOH/25% aq. NH 4 0H 70:30:5) to give 517 mg of 10 as a colorless oil.
Rf 0.60 (CHCI 3 /MeOH/25% aq. NH 4 0H 7:3:1).
'I-I-NMR: 3.64 OCH 3 3.38 (hr. NH); 2.91 (mn, CH); 2.74 (in, CR 2 2.50-2.70 (mn, 4 CH 2 2.47 CH 2 CO); 1.75-1.90 (mn, 2 CH 2
+NH
2 1.63 (i,
CH
2 1.45-1.55 (mn, 2 CR 2 1. 15-1.35 (mn, 11I C1 2 0.88 CH 3 CI-MS: 414 Example 16 2-Tridecyl- 1,5,9-triaza cyclotridecan-4 -one (11).
WO 02/10142 WO 0210142PCT/US01/24282 [0107] To a solution of 10 (190 mg, 0.46 mmol) in anhydrous xylene was added B(NMe 2 3 (0.09 ml, 75 mg, 0.5 mmol) and NH 4 CI (5 mg). The mixture was refluxed in N 2 atm. for 15 hi; after cooling to room temp., 5 ml of EtOH was added. After evaporation the residue was purified by column chromatography (SiO 2
CH
2 C12/MeOH!125% aq. NH 4 0H 70:30:3) to give 88 mg of 11 as a white solid, m.p. 72-73*.
Rf 0.28 (CHCl 3 /MeOH/25% aq. NH 4 0H 70:3:5).
'H-NMR: 8.56 (hr. s, CONH); 3.60-3.43 (in, 11H); 3.30-3. 10 (in, 1 H); 2.90-2.42 (in, 3 Gil 2 2.41 (dd, Jj 15.1, J 2 2.9, 1 2.14 (dd, J 1 15. 1, J 2 9.2, 1 1.8-1.1 (mn, 15 CH 2 0.87 CH 3 13 C-NMR: 172.11 GO); 55.72 CH); 49.42,48.74,45.06,40.96, 39.35, 33.80, 31.94 (7t, 7 Gil 2 29.66-29.76 (7 GH 2 29.61, 29.36, 28.05, 27.66, 26.93, 25.65 (6t,6 Gil 2 14.11 Gil 3 ESI-MS: 382 WO 02/10142 PCT/US01/24282 Example 17 Reduction and Alkylation of Cyclic Polyamines 0 Me
H
C
13
H
27 N I I Me Me (7c) LAH, THF 0 C, 4h 81% Me N N
H
C
13
H
27 N N I I Me Me (12) [0108] A solution of 7c (2.0 g) in dry THF (32 mL) was added carefully to a cooled (0 solution of LAII 4 eq) in dry TIIF (11 mL). The grey suspension was stirred at 0 oC for 10 min, and then heated to reflux (oil bath for 4 h. The reaction was cooled to 0 OC, diluted with ether (60 mL), quenched with water (4 mL), dried (Na 2
SO
4 filtered through a Celite pad, and concentrated under reduced pressure to give a thick oil, which was subjected to a flash column using CHCl 3 -EtOH-28% NH40H (70: 27: 3) as the eluant to afford 12 as a clear thick oil. 1 H NMR (250 MHz, CDC1 3 8 2.71-2.56 2.43-2.25 10H); 2.21 3H); 2.17 3H); 2.16 3H); 1.66-1.48 12H); 1.25 22H), 0.88 J= 6.9, 3H). "C NMR (62.5 MHz, CDC13) 8 62.39, 57.67, 57.16, 56.28, 54.85, 51.51, 49.37, 48.84, 43.04, 42.74, 36.79, 31.88, 31.46, 29.97, 29.62, 29.31, 28.32, 27.51, 27.40, 26.50, 25.12, 24.65, 22.64, 14.05.
MS-EI m/z 467.8(M+1) WO 02/10142 PCT/US01/24282 [0109] (Tetraamine 12 was converted to its tetra-HC1 salt, SL-11238, by dissolving it in MeOH, adding equal volume of concentrated HC1, stirring for min, and evaporating to dryness. The melting point of its crystals from EtOH was 241.5-244.5 oC. Anal. Calcd for C29H 7 0N 4 02C 4 formula for 12 plus four molecules of HCI and two molecules of H20: C, 53.69; H, 10.88; N, 8.64. Found: C, 53.29; H, 11.08; N, 8.32.) Me
H
C
13
H
27 N N Me Me (12)
CN
MeOH, O/N 100%
CN
Me
C
13
H
27
NN
Me Me (13) [0110] Acrylonitrile (1.4 mL) was added to a solution of 12 (1.0 g) in MeOH (5.5 mL), and the reaction was stirred at room temperature overnight (18 The solvent and excess acrylonitrile were evaporated under reduced pressure at 35 and the residue was purified by a flash column using CHCl 3 -EtOH-28%
NH
4 0H (70: 27: 3) as the eluant to give 13 (100%) as a clear thick oil. 1 H NMR (250 MHz, CDC13) 8 2.79 J= 6.7, 2H); 2.66-2.28 17H); 2.20 3H); 2.19 3H); 2.14 3H); 1.64-1.39 (m,10H); 1.26 24H); 0.88 J= 6.5, 3H). 1 3
C
NMR (62.5 MHz, CDC 3 8 119.14; 61.38; 56.95; 56.54; 54.86; 54.73; 52.12; WO 02/10142 PCT/US01/24282 51.70; 49.56; 43.12; 42.94; 36.16; 31.92; 30.05; 29.68; 29.35; 29.08; 28.33; 27.55; 26.23; 25.69; 24.65; 24.49; 22.67; 15.99; 14.08. MS-EI m/z 520.8
CN
Me N N
C
1 3
H
27 N N I I Me Me (13) Raney-Ni, NaOH aq. EtOH
H
2 (50psi), OIN 100%
NH
2 Me N N
C
13
H
27 N
N
Me Me (14) [0111] Raney nickel (0.8 g suspension in water) was added to a solution of 13 (1.0 g) and NaOH (5.0 eq) in 95% aq. EtOH (80 mL) in a Parr-shaker. The suspension was purged 5 times with hydrogen, and then shaken under hydrogen psi) overnight. The catalyst was filtered off through a Celite pad and destroyed with 2N HCI, and the filtrate was concentrated. The residue was dissolved in water (10 mL), extracted with CHC1 3 (4 x 30 mL), separated, and the organic layers were combined, dried (Na 2
SO
4 and concentrated under reduced pressure to afford 14 (quantitative, NMR TLC pure) as a clear thick oil.
[0112] 'H NMR (250 MHz, CDC13) 8 2.73 J= 6.8, 2H); 2.58-2.29 (m, 17H); 2.20 6H); 2.14 3H); 1.64-1.33 14H); 1.26 24H); 0.88 J= WO 02/10142 PCT/US01/24282 6.9, 3H). 1 3 C NMR (62.5 MHz, CDC1 3 8 61.50; 56.81; 56.18; 55.14; 54.60; 52.36; 52.11; 51.96; 43.14; 42.77; 40.79; 36.09; 31.77; 31.09; 29.89; 29.53; 29.20; 29.09; 27.90; 27.36; 26.05; 25.33; 24.38; 24.30; 22.52; 13.95. MS-El m/z 524.6 (M+1) [0113] (Pentaamine 14 was converted to its penta-HCI salt, SL-11239, by dissolving it in MeOH, adding equal volume of concentrated HC1, stirring for min, and evaporating to dryness. The melting point of its crystals from EtOH was 242.3-245.2 OC. Anal. Calcd for C 32 H7sN 5 0 2 C1 5 formula for 14 plus five molecules of HC1 and two molecules of H20: C, 51.78; H, 10.59; N, 9.44. Found: C, 51.68; H, 10.91; N, 9.14.) Example 18 Cyclic Polyamines as Anti-neoplastic Agents.
[0114] To assess the utility of the subject compounds in the treatment of neoplastic cell growth, the ability of the compounds to inhibit the in vitro growth characteristics of several commonly used cancer models were studied. The subject polyamines induce cell growth inhibitions in several cultured human prostate tumor cell lines such as LnCap, DuPro, and PC-3 as determined by the accepted MTT assay (Table 2) (Hansen, M.B. et al., "Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill," J. Immunol. Methods (1989)119(2):203-10). All three cell lines are sensitive to the cyclic polyamines with IDso values ranging between 500 nM to 2,600 nM. The results with the DuPro cell line are representative of the results with human prostate cell lines.
[0115] As shown in Figs. 1-14, the cyclic polyamines of the present invention have been shown to inhibit cell growth and even to cause cell death in accepted in vitro test cultures of human prostate cell cancer. The Figures are described in more detail below. The uptake of the cyclic polyamines by the DuPro cells and the resultant changes in the cellular polyamine levels are shown in Tables 3a and 3b.
WO 02/10142 PCT/US01/24282 [0116] As the hydrolysis of ATP is proposed as a possible mechanism for the antitumor activity of the cyclic polyamine analogs, assays to measure ATP hydrolysis were carried out. In a standardized method for measuring hydrolysis of ATP, a marked increase in ATP hydrolysis was observed in the presence of the cyclic polyamines (Figs. 15-21) as compared to the naturally occurring linear polyamine spermine.
[0117] The effects of the cyclic polyamines on the intracellular ATP content were measured using the Enliten ATP Assay test kit (Promega Corp., Madison, WI). The results of the cellular ATP measurements after a 72 hour incubation with varying concentrations of cyclic polyamines are shown in Figs.
22-24. All cyclic polyamines depleted the intracellular ATP pool. The relative abilities of the cyclic polyamines in depleting the intracellular ATP pool correspond to their relative cytotoxicities.
[0118] In Figs. 1-5 and Figs. 11-22, the X-axes depict the number of days after seeding DuPro cells and the Y-axes depict the number of cells harvested under control (no drug) conditions (Figs. 1-5) and in the presence of 10 pM of the drug SL-11174 (Fig. 5 pM SL-11197 (Fig. 5 plM SL-11199 (Fig. 10 PM SL-11200 (Fig. 4) and 5 pM SL-11208 (Fig. 2 pm of SL-11238 (Fig. 11) and upm of SL-11239 (Fig. 12).
[0119] The X-axes of Figs. 6-10 and Figs. 13-14 depict the concentrations of the cyclic polyamines and the Y-axes depict the fraction of surviving cells after days treatment with the drug SL-11174 (Fig. SL-11197 (Fig. SL-11199 (Fig. SL-11200 (Fig. SL-11208 (Fig. 10), SL-11238 (Fig. 13), and SL- 11239 (Fig. 14) as determined by the colony forming efficiency (CFE) assay (Wilson "Cytotoxicity and viablity assays." See Freshney, R.I. (ed) Animal Cell Culture: A Practical Approach. Oxford: IRL Press, 1992, p. 183.) [0120] The X-axes of Figs. 15-21 depict the concentrations of the polyamines and the Y-axes depict the relative increase in inorganic phosphate (PPi) released from 100 IM ATP in 24 hour in the presence of spermine and WO 02/10142 PCT/US01/24282 SL-11174 (Fig. 15), SL-11197 (Fig. 16), SL-11199 (Fig. 17), SL-11200 (Fig. 18), SL-11208 (Fig. 19), SL-11238 (Fig. 20), and SL-11239 (Fig. 21) as compared to the inorganic phosphate released from the same amount of ATP under identical conditions in the absence of any polyamines.
[0121] Marked growth inhibition and cell kill were observed for all cyclic polyamines at concentrations as low as 5 pM. Such high intracellular levels and such strong growth inhibitory and cytotoxic effects have not been reported for any other polyamine analogs tested so far. All cyclic polyamines were observed to be more efficient than the linear naturally occurring polyamine spermine in catalyzing hydrolysis of ATP.
[0122] The following standardized protocol was used to evaluate the test cultures and to generate data shown in Figs. 1-14. For Figs. 1-5 and Figs. 11-12, cells were seeded into 75 cm culture flasks with 15 ml of Eagle's minimal essential medium supplemented with 10% fetal calf serum and nonessential amino acids. The flasks were then incubated in a humidified 95% air/5% CO 2 atmosphere. The cells were grown for at least 24 h to ensure that they were in the log phase of growth, then treated with the polyamine analogs. Cells were harvested by treatment for 5 min with STV (saline A, 0.05% trypsin, 0.02% EDTA) at 37 The flasks were rapped on the lab bench, pipetted several times and aliquots of cell suspension were withdrawn and counted using a Coulter particle counter that had been standardized for counting each cell line using a hemacytometer.
[0123] For Figs. 6-10 and Figs. 13-14, cells were washed, harvested, and replated in quadruplicate at appropriate dilution into 60 mm plastic Petri dishes.
The Petri dishes were prepared not more than 24 hr in advance with 4 ml of supplemented Eagle's minimum essential medium containing 5-10% fetal bovine serum (standardized for each cell line). Cells were incubated for the previously standardized number of days in a 95% air/5% COz atmosphere. The plates were stained with 0.125% crystal violet in methanol and counted.
[0124] For Figs. 15-21, an ATP hydrolysis assay was standardized. In a 96 well microtiter plate, the first two columns were routinely used for standard 61 WO 02/10142 PCT/US01/24282 curve generation. For the standard curve, 40 Al of 0-70 pM phosphate buffer was used by serially diluting 1 mM NaH 2
PO
4 solution in 1 N HC1. For ATP hydrolysis, the rest of the microtiter plate was equally divided into two sections to run two analogs at a time. Each section was divided into the appropriate number of columns to serially dilute each analog between 0 10 mM in 29 ul 2N HCI for the final concentration of2 N HC1. Each drug concentration was run in quadruplicate. Equal volumes of 500 gM ATP solution (pH 7.5) were added to each well and the plates were incubated at 370 C for appropriate lengths of time between 2-24 h. At the end of the incubation period, 160 pl of coloring agent (0.045% Malachite Green in water and 4.2% ammonium molybdate in 4 N HC1 (3:1 was added and the plates were incubated at 370 C for another 30 mins.
All plates were read at 595 nm using a Emax precision microplate reader (Molecular Device, San Jose, CA). A control plate containing analog solutions without ATP was created for each experiment. Control plate reading was subtracted from each experimental plate and all data was normalized to ATP hydrolysis at zero concentration ofpolyamine analog. The average and standard deviation for quadruplicate runs were plotted.
[0125] For the data shown in Table 2, an accepted MTT assay protocol was used. A trypsinized cell suspension was diluted to seed 80 pl suspension containing 500 cells in each well of a 96 well microtiter plates and incubated overnight at 37 0 C in a humidified incubator in 5% CO 2 Twenty pl of appropriately diluted stock solution of each drug was added to the middle 8 columns of cell suspension in the microtiter plates. Each drug concentration was run in quadruplicate. Outer columns of the plates were used for buffer controls.
Cells were incubated with the drug for 6 days at 37 0 C in 5% CO2/H 2 0 atmosphere. Twenty five pl of 5 mg/ml solution of 3-(4,5-dimethythiazol-2-yl)-2, tetrazolium bromide (MTT) was added to each well and incubated for 4 hours at 370 C in 5% C0 2
/H
2 0 incubator. Cells were lysed by incubating overnight with 100 l lysis buffer (500 ml of the lysis buffer containing: 100 g lauryl sulfate (SDS), 250 ml ofN,N-dimethyl formamide in 2 ml of glacial acetic acid, pH The color was monitored at room temperature at 570 nm in a 62 WO 02/10142 PCT/US01/24282 E-max Precision Microplate Reader (Molecular Devices Corporation, Sunnyvale, CA) and data were analyzed using cell survival software supplied by Molecular Devices Corporation.
[0126] For data shown in Tables 3a and 3b, intracellular polyamine levels were determined using a standard protocol. About 0.5-1 x 106 cells were taken from harvested samples and centrifuged at 1000 rpm at 4 0 C for 5 min. The cells were washed twice with chilled Dulbecco's isotonic phosphate buffer (pH 7.4) by centrifugation at 1000 rpm at 4 0 C and resuspended in the same buffer. After the final centrifugation, the supernatant was decanted, and 250 pl of 8% sulfosalycilic acid was added to the cell pellet. The cells were then sonicated, and the mixture was kept at 4° C for at least 1 h. After centrifugation at 8,000 g for 5 min, the supernatant was removed for analysis. An appropriate volume (50-100 gl) was fluorescence-labeled by derivatizing with dansyl chloride. Labeled polyamines were loaded onto a C-18 high-performance liquid chromatography column and separated by gradient elution with acetonitrile/water at 50 0 C. Peaks were detected and quantitated using a Shimadzu HPLC fluorescence monitor coupled with a Spectra-Physics peak integrator. Because polyamine levels vary with environmental conditions, control cultures were sampled for each experiment.
[0127] For the data shown in Figs. 22-24, a protocol was standardized using the Enliten ATP Assay System (Promega Corp., Madison, WI).
Approximately lx106 cells from each treatment flask were harvested, counted, washed twice with chilled PBS and the cell pellets were stored at 4 0 C overnight.
On the following day the pellets were resuspended in calculated volumes of treatment buffer (Enliten ATP Assay System, Promega Corp.) to remove the extracellular ATP. An aliquot of 140 pl of the cell suspension containing 50,000 cells was plated in each well of a 96 well luminometer plate and was allowed to equilibrate to room temperature. Each compound concentration was plated in quadruplicate. To each well, 40 pl Extraction Buffer (Promega Enliten ATP Assay System) was added and the plates were placed in an EG&G luminometer (Berthold Inc., Bundoora, Victoria, Australia). Then 40 gl L/L Reagent (Promega Enliten ATP Assay System) containing luciferase/luciferin mixture in assay buffer 63 WO 02/10142 PCT/US01/24282 was injected and each well was read for 5 seconds after a one-second delay time.
The relative changes in cellular ATP content were measured as relative light units (RLU) generated by the luciferase/luciferin reaction.
WO 02/10142 WO 0210142PCT/US01/24282 Table 2 Effects of Cyclic Polyamines on Prostate Tumor Cell Growth (IDso values) Analog ID 5 o (jiM)values DuPro PC-3 LnCap SL-1 1174 0.83 0.60 2.20 SL-11197 0.58 0.5 2.60 SL-11199 1.20 1.4 1.50 SL-1 1200 1.40 1.30 Nd SL-1 1208 1.80 1.70 Nd Nd Not determined WO 02/10142 WO 0210142PCT/USOI/24282 Table 3a Polyamine Levels in DuPro Cells Treated with Low Conc. of Cyclic Polyamine Analogs.
Polyamine Polyamines (nMoleS/10 6 Cells) On Polyamines (nniolesllO 6 Cells) on Analogs Day 4 of Treatment Day 6 of Treatment used Put Spd Spin Analog Put Spd Spin Analog Control 0.83 1.58 2.48 0.31 0.73 9 1.07 SL- ND ND 0.002 2.788 ND ND 0.001 17.206 11174 (1 JIM) SL- ND ND 0.004 47.566 ND ND 0.002 35.913 11197 pM) SL- ND ND 0.002 26.959 ND 0.005 0.003 26.841 11199 pM_) SL- 0.004 0.029 0.089 10.089 ND 0.014 0.043 46.776 11200 (G W) ND =Not Detectable. Put putrescine; Spd spermidine; Spin spermine; Analog as indicated in leftmost column.
WO 02/10142 WO 0210142PCT/US01/24282 Table 3h Polyammne Levels in DuPro, Cells Treated with 2 jiM Cyclic Polyamine Analogs.
Polyamine Polyamines (umoles/lO6 Cells) on Polyamines (nmoles/10 6 Cells) on Analogs Day 4 of Treatment Day 6 of Treatment used Put Spd Spin Analog Put Spd Spin Analog Control 0.832 1.579 2.484 0.31 0.39 1.07 SL- ND ND 0.001 25.074 ND ND 0.0021 21.472 11174 SL- ND ND ND 49.072 ND ND ND 42.341 11197 SL- ND ND ND 17.198 ND ND ND 10.241 11199 SL- 0.020 0.027 0.095 5.989 0.011 0.018 0.053 49.309 11200 ND Not Detectable. Put =putrescine; Spd spermidine; Spin spermine; Analog as indicated in leftmost column.
WO 02/10142 PCT/US01/24282 [0128] All references, publications, patents and patent applications mentioned herein are hereby incorporated by reference herein in their entirety.
[0129] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent to those skilled in the art that certain changes and modifications may be practical. Therefore, the description and examples should not be construed as limiting the scope of the invention, which is delineated by the appended claims.
Claims (28)
1. A compound of the formula ,O M N k "0 Y 00 A SR N NY Y wherein Al, each A 2 (if present), and A 3 are independently selected from CI-C 8 alkylene; wherein each Y is independently selected from H or CI-C 4 alkyl; wherein M is selected from Ci-C 4 alkylene; wherein k is 0, 2, or 3; and wherein R is selected from CI-C 32 alkyl; and all stereoisomers and salts thereof.
2. A compound of the formula O M N NY Y I /A 3 A 2 Y Y wherein A, and A 3 are independently selected from Ci-C 8 alkylene; wherein A 2 is independently selected from Ci-C 3 alkylene or C 5 -C alkylene; wherein each Y is independently selected from H or Ci-C 4 alkyl; wherein M is selected from Ci-C 4 alkylene; and wherein R is selected from CI-C 3 2 alkyl; and all stereoisomers and salts thereof. 165894 1.doc C N 3. A compound of the formula 0 A A2 M N/ A NY R N N SY Y wherein A, and A 3 are independently selected from CI-Cs alkylene; wherein A 2 is independently selected from Ci-C 8 alkylene; wherein each Y is independently selected from H or C 2 -C 4 alkyl; wherein M is selected from CI-C 4 alkylene; and wherein R is selected from Ci-C 32 alkyl; and all stereoisomers and salts thereof.
4. A compound according to claim 1, 2, or 3, wherein each Y group is -H. A compound according to claim 1 or 2, wherein each Y group is -CHl 3
6. A compound according to claim 1, wherein each A 2 (if present), and A 3 are independently selected from C 2 -C 4 alkylene.
7. A compound according to claim 1, 2, or 3, wherein M is -CH 2
8. A compound according to claim 2, wherein A, and A 3 are independently selected from C 2 -C 4 alkylene, and A 2 is selected from the group consisting of C 2 -C 3 alkylene and Cs alkylene.
9. A compound according to claim 3, wherein Al and A 3 are independently selected from C 2 -C 4 alkylene, and A 2 is selected from the group consisting of C 2 -Cs alkylene. 165894 1.doc N 10. A method of synthesizing a compound of the formula O M N/A NY-A2 k M N 00 R N 3 NY Y O 5 wherein AI, each A 2 (if present), and A 3 are independently selected from CI-Cs alkylene; wherein each Y is independently selected from H or Ci-C 4 alkyl; wherein M is selected from Ci-C 4 alkylene; wherein k is 0, 1,2, or 3; and wherein R is selected from CI-C 3 2 alkyl; comprising the steps of: reacting an o-halo alkyl alkanoate with an aldehyde or ketone-containing compound to give an alkene-containing alkanoate compound; reacting the alkene-containing alkanoate compound with a compound containing two primary amino groups and optionally containing secondary amino groups to effect addition of one of the amino groups across the double bond; cyclizing the other amino group with the alkanoate group to form an amide bond; and optionally alkylating the secondary amino groups if present.
11. A method according to claim 10, wherein the co-halo alkyl alkanoate is ethyl bromoacetate.
12. A method according to claim 11, wherein the aldehyde or ketone-containing compound is an aldehyde-containing compound.
13. A method according to claim 1 wherein the step of reacting an co-halo alkyl alkanoate with an aldehyde or ketone-containing compound to give an alkene- containing alkanoate compound is performed by reacting the co-halo alkyl alkanoate with triphenylphosphine. 165894 1.doc N 14. A method according to claim 11, wherein the compound containing two primary amino groups is selected from the group consisting of H 2 N-AI-(NH-A 2 )k-NH-A 3 -NH 2 wherein each A 2 (if present), and A 3 are independently selected from Ci-C 8 alkylene and k is 0, 1,2, or 3. C 15. A method according to claim 14, wherein the compound containing two primary amino groups is selected from the group consisting of spermine, spermidine, and 00 putrescine. S 10 16. A method according to claim 11, wherein the step of cyclizing the other amino C group with the alkyl alkanoate group to form an amide bond is performed by reacting the compound with antimony (III) ethoxide.
17. A method according to claim 11, wherein the step of optionally alkylating any secondary amino groups if present is performed by reacting the compound first with an aliphatic aldehyde to result in a Schiff base, then reducing the Schiff base, resulting in alkylation of the secondary amino groups.
18. A method according to claim 17, wherein the step of reducing the Schiff base is performed by using the reagent NaCNBH 3
19. A method of synthesizing a compound of the formula 0 M N A NY-A2 k R N 3NY Y wherein A, is C 3 alkylene, and each A 2 (if present) and A 3 are independently selected from CI-C 8 alkylene; wherein each Y is independently selected from H or CI-C 4 alkyl; wherein M is selected from Ci-C 4 alkylene; wherein k is 0, 1, 2, or 3; 165894 1.doc (N and wherein R is selected from Ci-C 32 alkyl; comprising the steps of: condensing a compound comprising a primary amino group and a hcxahydropyrimidine moiety with an a,p-unsaturated ester compound such that the primary amino group adds at the P-position of the unsaturated ester compound, whereby the primary amino C group is converted to a secondary amino group; cleaving the methylene bridge of the hexahydropyrimidine moiety to generate a 00 secondary amino group and a newly-generated primary amino group; and Scondensing the newly-generated primary amino group with the ester group to form an S 10 amide group. A method according to claim 19, wherein the ta,-unsaturated ester is of the formula (C -C 8 alkyl)-O-C(=O)-CH=CH-(C-C 3 2 alkyl).
21. A method according to claim 19, wherein the compound comprising a primary amino group and a hexahydropyrimidine moiety is of the formula H 2 N-A 3 -(NY-A 2 )j-N NH wherein each A 2 (if present) and A 3 are independently selected from CI-Cs alkylene; wherein each Y is independently selected from H or CI-C 4 alkyl; and wherein j is 0, 1, 2, or 3.
22. The method according to claim 21, wherein j is 0.
23. A method according to claim 22, wherein A 3 is C 4 alkylene.
24. A method according to claim 19, wherein the step of cleaving the methylene bridge of the hexahydropyrimidine moiety is performed with anhydrous HCI in an alcoholic solvent. 1658941 doc C
25. A method according to claim 19, wherein the step of condensing the newly- generated primary amino group with the ester group to form an amide group is performed with the reagent B(N(CH 3 2 3
26. A method of treating cancer or a disease characterized by uncontrolled cell e proliferation in an individual in need of such treatment, comprising the step of administering one or more compounds of claim 1,2, or 3. 00
27. A method of depleting ATP in a cancerous cell, comprising the step of O 10 administering one or more compounds of claim 1, 2, or 3 to the cell.
28. A compound of the formula x A 4 S AjNY-A2 M N k Y R N A3 Y wherein Ai, each A 2 (if present), and A 3 are independently selected from Ci-C 8 alkylene; wherein A 4 is selected from Ci-Cs alkylene or a nonentity; X is selected from -CN, -NH 2 -C(=O)-Ci-C 8 alkyl, or -NHZ, with the provisos that when A 4 is a nonentity, X is -C(=O)-Ci-Cs alkyl, or and that when X is -Z, A 4 is a nonentity; Z is selected from the group consisting of an amino protecting group, an amino capping group, an amino acid, and a peptide; wherein each Y is independently selected from H or Ci-C 4 alkyl; wherein M is selected from CI-C 4 alkylene; wherein k is 0, 1,2, or 3; and wherein R is selected from C 1 -C 32 alkyl; and all stereoisomers and salts thereof. 165894_1.doc S29. A compound according to claim 28, wherein A 4 is a nonentity, X is and each SY is-CH 3 A compound according to claim 29, wherein M is -CH 2 k is 1, A, and A 3 are -CH 2 CH 2 CH 2 and the single A 2 group is -CH 2 CH 2 CH 2 CH2-.
31. A compound according to claim 30, wherein R is -C 1 3 H 27 00
32. A compound according to claim 28, wherein A 4 is CI-Cg alkylene, X is -NHZ, O 10 and and Z is selected from one of the 20 genetically encoded amino acids, a peptide of N the formula acetyl-SKLQL-, a peptide of the formula acetyl-SKLQ--alanine-, or a peptide of the formula acetyl-SKLQ-.
33. A method of synthesizing a compound according to claim 28, wherein A 4 is a nonentity and X is comprising reducing the carbonyl of the amide group of a compound of the formula X 0 A 4 M I A, NY-A 2 k M N k Y R N 1 A 3 NY Y wherein A 4 is a nonentity and X is -H.
34. A method of synthesizing a compound according to claim 28, wherein A 4 is C 2 alkylene, each Y is selected from CI-C 4 alkyl, and X is -CN, comprising reacting a compound of the formula 165894 1.doc H SM /AINY-A 2 M N k M R) N ANY Y 00 wherein each Y is selected from Ci-C 4 alkyl, with a compound of the formula H 2 C=C-lCN. A method of synthesizing a compound according to claim 28, wherein A 4 is C 3 alkylene and X is -NH 2 comprising reducing the nitrile group of a compound of the formula CN A 4 SA NY-A2 M N k Y R N NY Y where A 4 is selected from Ci-C 7 alkylene, to an amino group.
36. A compound substantially as hereinbefore described with reference to any one of the figures and/or the examples and/or the preferred embodiments excluding, if any, comparative examples.
37. A method of synthesizing a compound substantially as hereinbefore described with reference to any one of the figures and/or the examples and/or the preferred embodiments excluding, if any, comparative examples. 165894 1.doc
38. A method of treating cancer or disease substantially as hereinbefore described with reference to any one of the figures and/or the examples and/or the preferred embodiments excluding, if any, comparative examples. C^ 39. A method of depleting ATP in a cancerous cell substantially as hereinbefore described with reference to any one of the figures and/or the examples and/or the 00 preferred embodiments excluding, if any, comparative examples. C Dated this eighteenth day of June 2007 SLIL Biomedical Corporation Patent Attorneys for the Applicant: F B RICE CO 165894 l.doc
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22252200P | 2000-08-02 | 2000-08-02 | |
US60/222,522 | 2000-08-02 | ||
PCT/US2001/024282 WO2002010142A1 (en) | 2000-08-02 | 2001-08-02 | Cyclic polyamine compounds for cancer therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2001278143A1 AU2001278143A1 (en) | 2002-05-09 |
AU2001278143B2 true AU2001278143B2 (en) | 2007-08-09 |
Family
ID=22832553
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001278143A Ceased AU2001278143B2 (en) | 2000-08-02 | 2001-08-02 | Cyclic polyamine compounds for cancer therapy |
AU7814301A Pending AU7814301A (en) | 2000-08-02 | 2001-08-02 | Cyclic polyamine compounds for cancer therapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU7814301A Pending AU7814301A (en) | 2000-08-02 | 2001-08-02 | Cyclic polyamine compounds for cancer therapy |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1305299A1 (en) |
JP (1) | JP2004505112A (en) |
AU (2) | AU2001278143B2 (en) |
CA (1) | CA2417064A1 (en) |
IL (1) | IL153864A0 (en) |
MX (1) | MXPA03000905A (en) |
WO (1) | WO2002010142A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004002991A1 (en) * | 2002-06-26 | 2004-01-08 | Cellgate, Inc. | Porphyrin-polyamine conjugates for cancer therapy |
RU2008108632A (en) | 2005-08-10 | 2009-09-20 | Джонс Хопкинс Юниверсити (Us) | POLYAMINES USED IN ANTI-PARASITIC AND ANTI-CANCER THERAPIES AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS |
WO2009114614A2 (en) | 2008-03-11 | 2009-09-17 | Yale University | Compositions and methods for controlled delivery of inhibitory ribonucleic acids |
US9822364B2 (en) | 2008-03-11 | 2017-11-21 | Yale University | Compositions and methods for controlled delivery of inhibitory ribonucleic acids |
US9895451B2 (en) | 2011-12-02 | 2018-02-20 | Yale University | Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof |
US10465042B2 (en) | 2011-12-02 | 2019-11-05 | Yale University | Poly(amine-co-ester) nanoparticles and methods of use thereof |
WO2013082529A1 (en) | 2011-12-02 | 2013-06-06 | Yale University | Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery |
EP2822936B1 (en) | 2012-03-07 | 2021-09-08 | The McLean Hospital Corporation | Aminoquinoline derivatives and uses thereof |
GB2517375A (en) * | 2012-05-15 | 2015-02-18 | Thermo Electron Scient Instr | Ultra broadband multilayer dielectric beamsplitter coating |
US11918695B2 (en) | 2014-05-09 | 2024-03-05 | Yale University | Topical formulation of hyperbranched polymer-coated particles |
EP3721875B1 (en) | 2014-05-09 | 2023-11-08 | Yale University | Particles coated with hyperbranched polyglycerol and methods for their preparation |
US10815276B2 (en) | 2014-05-21 | 2020-10-27 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
JP6807831B2 (en) | 2014-05-21 | 2021-01-06 | エントラーダ セラピューティクス,インコーポレイテッド | Cell-penetrating peptide, and how to make and use it |
EP3185880B1 (en) | 2014-08-27 | 2020-02-12 | Ohio State Innovation Foundation | Improved peptidyl calcineurin inhibitors |
US10682422B2 (en) | 2014-11-18 | 2020-06-16 | Yale University | Formulations for targeted release of agents under low pH conditions and methods of use thereof |
WO2016081621A1 (en) | 2014-11-18 | 2016-05-26 | Yale University | Formulations for targeted release of agents under low ph conditions and methods of use thereof |
CA3014795A1 (en) | 2016-02-16 | 2017-08-24 | Yale University | Compositions and methods for treatment of cystic fibrosis |
EP3416976A2 (en) | 2016-02-16 | 2018-12-26 | Yale University | Compositions for enhancing targeted gene editing and methods of use thereof |
WO2017197128A1 (en) | 2016-05-11 | 2017-11-16 | Yale University | Poly(amine-co-ester) nanoparticles and methods of use thereof |
WO2018187493A1 (en) | 2017-04-04 | 2018-10-11 | Yale University | Compositions and methods for in utero delivery |
WO2019148194A2 (en) | 2018-01-29 | 2019-08-01 | Ohio State Innovation Foundation | Peptidyl inhibitors of calcineurin-nfat interaction |
EP3755351A4 (en) | 2018-02-22 | 2021-11-24 | Entrada Therapeutics, Inc. | Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy |
EP3790890A4 (en) | 2018-05-09 | 2022-03-02 | Ohio State Innovation Foundation | Cyclic cell-penetrating peptides with one or more hydrophobic residues |
US20210189431A1 (en) | 2018-08-10 | 2021-06-24 | Yale University | Compositions and methods for embryonic gene editing in vitro |
US11814464B2 (en) | 2019-04-29 | 2023-11-14 | Yale University | Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof |
WO2020257776A1 (en) | 2019-06-21 | 2020-12-24 | Yale University | Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof |
WO2020257779A1 (en) | 2019-06-21 | 2020-12-24 | Yale University | Hydroxymethyl-modified gamma-pna compositions and methods of use thereof |
US20220280656A1 (en) | 2019-07-31 | 2022-09-08 | Yale University | Compositions and methods for treating sickle cell disease |
EP4168471A1 (en) | 2020-06-19 | 2023-04-26 | Yale University | Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery |
US20220031633A1 (en) | 2020-07-28 | 2022-02-03 | Yale University | Poly(amine-co-ester) polymeric particles for selective pulmonary delivery |
US20230172870A1 (en) | 2021-12-08 | 2023-06-08 | Yale University | Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues |
WO2023159189A1 (en) | 2022-02-18 | 2023-08-24 | Yale University | Branched poly(amine-co-ester) polymers for more efficient nucleic expression |
CN117088825A (en) * | 2023-10-12 | 2023-11-21 | 成都威斯津生物医药科技有限公司 | Ionizable lipid, pharmaceutical composition containing same and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4999349A (en) * | 1990-03-22 | 1991-03-12 | Bristol-Myers Squibb Co. | BU-4164E - A and B, prolyl endopeptidase inhibitors |
AU2058197A (en) * | 1996-02-27 | 1997-09-16 | Eli Lilly And Company | Pharmaceutical compounds |
-
2001
- 2001-08-02 CA CA002417064A patent/CA2417064A1/en not_active Abandoned
- 2001-08-02 MX MXPA03000905A patent/MXPA03000905A/en not_active Application Discontinuation
- 2001-08-02 JP JP2002516274A patent/JP2004505112A/en not_active Withdrawn
- 2001-08-02 IL IL15386401A patent/IL153864A0/en unknown
- 2001-08-02 AU AU2001278143A patent/AU2001278143B2/en not_active Ceased
- 2001-08-02 WO PCT/US2001/024282 patent/WO2002010142A1/en active IP Right Grant
- 2001-08-02 EP EP01956110A patent/EP1305299A1/en not_active Withdrawn
- 2001-08-02 AU AU7814301A patent/AU7814301A/en active Pending
Non-Patent Citations (4)
Title |
---|
J Nat Prod (1991) 54(6) 1531-1542 * |
J Nat Prod (1996) 59(9) 850-853 * |
Phytochemistry (1995) 39(1) 247-249 * |
Phytochemistry (1996) 42(4) 1211-1215 * |
Also Published As
Publication number | Publication date |
---|---|
MXPA03000905A (en) | 2003-06-24 |
JP2004505112A (en) | 2004-02-19 |
IL153864A0 (en) | 2003-07-31 |
CA2417064A1 (en) | 2002-02-07 |
WO2002010142A1 (en) | 2002-02-07 |
EP1305299A1 (en) | 2003-05-02 |
AU7814301A (en) | 2002-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001278143B2 (en) | Cyclic polyamine compounds for cancer therapy | |
AU2001278143A1 (en) | Cyclic polyamine compounds for cancer therapy | |
US20050130949A1 (en) | Cyclic polyamine compounds for cancer therapy | |
US7453011B2 (en) | Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor | |
US7312244B2 (en) | Polyamine analog-amino acid conjugates useful as anticancer agents | |
US6794545B1 (en) | Conformationally restricted polyamine analogs as disease therapies | |
AU2009200639A1 (en) | Oligoamine compounds and derivatives thereof for cancer therapy | |
JP7368637B2 (en) | Compounds for inhibiting fibroblast activation proteins | |
US7026347B2 (en) | Porphyrin-polyamine conjugates for cancer therapy | |
WO2022177002A1 (en) | Boron neutron capture therapy (bnct) probe | |
JP3985856B2 (en) | Polyaryl antitumor agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TC | Change of applicant's name (sec. 104) |
Owner name: SLIL BIOMEDICAL CORPORATION; UNIVERSITY OF ZURICH Free format text: FORMER NAME: SLIL BIOMEDICAL CORPORATION |
|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |